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5I Foreword
Cannabis is the illicit drug used most widely and most frequently in Europe; for those who 
experiment with banned substances in their youth, cannabis is the first, and in many cases 
the only, controlled drug they will experience. For most, use will be experimental, 
occasional and short-lived — but an important minority of consumers will go on to develop 
a long-term attachment to the drug and report periods of sustained and regular use. Over 
the last decade, our understanding of the potential problems that can be associated with 
the use of cannabis has grown substantially. Acute problems, though rare, can occur even 
among naive, occasional and inexperienced users — sometimes sufficiently serious to 
require emergency responses — with implications for drug prevention and harm-reduction 
activities. It is the chronic use of cannabis, however, that is of particular concern in the 
context of the need for drug-treatment interventions — and it is this area which is explored 
in detail in this new EMCDDA publication.
A substantive backdrop to this report is that we now see increasing numbers of young 
people presenting for, or being referred to, treatment for cannabis-related problems. Until a 
few years ago, the majority of those seeking treatment for their drug problems for the first 
time in their life were opioid users. However, that has changed, and now the largest group 
of first-time treatment entrants is those seeking help for problems related to cannabis use. 
Opioid use, it must be noted, still accounts by far for the greater burden on European 
drug-treatment services. Cannabis treatment covers a range of therapeutic interventions, 
some of which are relatively low-intensity. Nonetheless, it is clear that cannabis use now 
represents, and is increasingly recognised as, a major issue for European drug-treatment 
services and therefore an area of growing importance for defining what constitutes an 
effective and evidence-based approach. 
It is, in my view, both timely and appropriate that the EMCDDA is addressing the treatment 
of cannabis use disorders when, in many parts of the world, the drug is high on the political 
agenda. However, it is important to note that regardless of discussions on the most 
appropriate control or regulatory frameworks for this drug, the question of how best to 
respond to those individuals who experience problems with their cannabis use remains an 
important one. This report is only possible because the evidence base in this area has 
grown substantially in recent years and many countries now have considerable experience 
of successful engagement with this client group. We are therefore indebted to the 
researchers and practitioners whose work is reflected here. Drawing on the research 
literature and experiential learning, this publication presents an in-depth and up-to-date 
review of what works in treating cannabis use disorders and maps out the geography of 
cannabis treatment in Europe. 
Looking towards the future, the challenges we will face in this area are not easy to predict. 
We have observed seismic shifts in the cannabis market, with unprecedented changes in 
the way the drug is produced and distributed. There is also a growing debate on cannabis 
control, changes in patterns of use and, to some extent at least, a growing diversity in the 
implementation of control and regulatory frameworks used for this drug. Regardless of the 
implications of these factors on either the prevalence or patterns of cannabis use we will 
see in Europe, we can say, with some confidence, that providing effective treatment for 
those with cannabis use disorders is likely to be an objective of growing importance in 
European drug policy. 
Wolfgang Götz 
Director, EMCDDA

7I Executive summary
I Background
Individuals with cannabis use disorders have historically presented in drug treatment 
settings in Europe; however, over the past several years, the numbers seeking treatment 
for problems related to cannabis use have increased, both in absolute and relative terms. 
In parallel, many countries in Europe have implemented, expanded or modified national 
treatment programmes to better serve this population.
This publication aims to provide experts and policymakers with an analysis of the latest 
information available on treatment for cannabis use to ensure that they have a firm 
foundation for decision-making. More specifically, it provides a review of recent research 
on available treatments for adolescent and adult cannabis users. In addition, it describes 
and analyses selected cannabis-specific programmes currently offered in the European 
Union and provides a brief overview of the availability and type of treatments for 
individuals with cannabis use disorders in each EU Member State. Finally, it compares 
indicators of treatment needs with estimated provision of treatment.
I Methods and data sources
Materials and research publications from the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) were searched to identify all the systematic reviews, narrative 
reviews and individual studies (randomised controlled trials and observational studies) on 
the effectiveness of treatment for cannabis users (adolescents or adults) published 
between 2008 and 2012. Publications in three databases (PubMed, EBSCO and Google 
Scholar) were searched for terms related to treatment of cannabis-related disorders. 
Exclusion criteria were set for studies focusing only on either alcohol or tobacco.
Data on cannabis-specific treatment programmes in the 28 EU Member States, Turkey and 
Norway were obtained from the EMCDDA Annual reports and Statistical bulletins from 
2008 to 2012 (EMCDDA 2008–2012a, b) and through an ad hoc data collection with the 
support of the EMCDDA’s network of national focal points (the Reitox network).
I Findings
A variety of evidence-based treatments were found to be available for cannabis use 
disorders. Compared with standard treatment in place (treatment as usual), these 
interventions are more effective in reducing the frequency and quantity of substance use, 
as well as the severity of substance use-related problems.
No individual empirically supported treatment emerged as being significantly more 
effective than any other empirically supported treatment. However, a combination of 
cognitive behavioural therapy (CBT) and motivational interviewing (MI) appeared to be 
more cost-effective than other treatment approaches in several studies.
While multidimensional family therapy (MDFT) may have some advantages (e.g. better 
treatment adherence) over other treatment approaches for adolescents, a combination of 
CBT, MI and contingency management (CM) appears to be the most effective treatment 
approach for adults.
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Most countries in Europe offer evidence-based treatment programmes for cannabis use 
disorders. These follow either a general substance use treatment approach or a cannabis-
specific approach.
Of the 30 European countries surveyed, all bar Sweden provided information on the 
provision of cannabis treatment. Fifteen of the countries provide at least one cannabis-
specific treatment programme. In the remaining countries, individuals with cannabis use 
disorders are treated in the same programmes as individuals with other substance use 
disorders.
Treatment programmes are administered in both outpatient and inpatient settings by a 
variety of different service providers, including professionals, para-professionals and 
laypeople. The most frequently offered evidence-based cannabis-specific interventions in 
Europe are based on MDFT, CBT and MI/MET (motivational enhancement therapy). In 
most of the countries offering cannabis-specific treatment, coverage of the affected 
population is rated as ‘good’, and experts report that the majority of individuals in need of 
treatment for cannabis use disorders have access to treatment. A few countries, however, 
have only limited coverage, sometimes despite high overall levels of need. Less is known 
about the accessibility of treatment for cannabis use disorders in countries that do not 
offer cannabis-specific interventions.
I Conclusions
Although many countries in Europe offer quite effective and comprehensive treatment 
programmes for cannabis use disorders, there is still potential for further improvement. In 
some cases, no evidence-based treatment for cannabis use disorders is offered; in other 
cases, availability may not be sufficient. Collaboration between treatment providers, 
general healthcare and the criminal justice system can help to reach people in need 
through referrals. While most of those receiving treatment for cannabis-related problems 
are treated in outpatient settings, treatment in inpatient settings is also reported by the 
majority of countries. Given the young age and often limited level of problems experienced 
by many cannabis users, Internet-based interventions are a promising approach which is 
already supported by some evidence.
Addressing shortcomings and limitations will help to increase the overall availability and 
quality of treatment for cannabis use disorders in Europe, which may reduce the potential 
long-term negative effects in this relatively young group of drug users. The high levels of 
cannabis use in some parts of Europe, coupled with growing challenges to the drug’s 
status as a controlled substance and possible shifts in the social acceptability of the drug, 
underline the importance of meeting current treatment needs and remaining vigilant for 
future changes.
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I Introduction
In Europe, cannabis is now the drug most often cited as the main reason for seeking help 
by those entering drug treatment for the first time in their life. This is a recent development, 
reflecting in part an expansion in the provision of treatment for problems related to 
cannabis use. It may also reflect the status of cannabis as the most used illicit drug, with 
an estimated 14.6 million Europeans aged 15–34 using the drug in the last year and 
3 million using it daily or near-daily (EMCDDA, 2014b; Thanki et al., 2012). These 
developments have taken place against a backdrop of major change in the European 
cannabis market, which has been transformed over the past decade by the spread of 
domestic cultivation of the drug, lowering the barriers between producer and consumer; 
furthermore, the potency of cannabis products is increasing (EMCDDA, 2012a).
Treatment for cannabis-related problems, in contrast to treatment for problems related to 
heroin use, relies primarily on psychosocial approaches combining elements of classical 
psychotherapy with social support and care. Various psychological interventions to treat 
drug dependence exist, and these may be tailored to the needs of the users of one drug or 
they may be provided to users of any drug. With the large numbers entering treatment each 
year in Europe, where drug treatment is paid for largely from public funds, effectiveness is a 
key consideration for policy. Research into the effectiveness of treatment approaches for 
cannabis problems, however, is still relatively new, and when it was last reviewed by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) no conclusive 
evidence was found for any specific treatment (Bergmark, 2008). The present publication 
includes an updated review of the literature on treatment for cannabis problems, with the 
aim of helping policymakers identify the interventions most likely to succeed.
This publication has two principal aims. The first is to examine the evidence base underlying 
interventions for cannabis-related problems. Among the main questions addressed are the 
following: ‘For what interventions is there evidence of effectiveness?’ and ‘Does the evidence 
favour cannabis-specific interventions over general substance use treatment?’ The second aim 
is to map the availability and provision of cannabis treatment in Europe, based on information from 
the 28 EU Member States, Turkey and Norway. Here, in addition to describing cannabis treatment 
programmes, the relationship between treatment needs and treatment provision is addressed.
The first chapter provides the reader with the background information necessary to 
understand the rest of the book. The topics covered include the prevalence of cannabis use 
in Europe and the social, health and legal consequences of use of the drug. The provision of 
treatment for cannabis users is looked at, as is the question of determining treatment need. 
In an overview of treatment for cannabis problems in Europe, a distinction is made between 
cannabis-specific and general substance use treatment approaches. The main psychosocial 
approaches to treating cannabis-related problems in Europe are described here. This chapter 
also describes the methods and sources of data used in the study.
In the second chapter, the evidence for the effectiveness of the various interventions is 
reviewed, with treatments for adolescents and adults considered separately. This chapter 
also reviews the research on telephone and Internet interventions. The chapter closes by 
examining the factors and mechanisms that influence effectiveness.
The treatments available in Europe for cannabis-related problems are reviewed in the third 
chapter. Information is presented on the treatment options available in each country, with 
a particular focus on the major cannabis-specific programmes in Europe. The fourth 
chapter looks at the calculation of unmet treatment needs.
The findings of the study are brought together in a final chapter, where the implications for 
policy and practice are assessed.
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I  Cannabis in the European Union:  use and problematic use
Population surveys indicate that cannabis is the most widely 
used illicit substance in most European countries. The most 
recent estimates suggest that 5 % of adults (15–64 years) 
in the European Union, or 18 million adult Europeans, used 
cannabis in the last year; 74 million adult Europeans 
reported having using cannabis at least once in their life 
(EMCDDA, 2014b). To put Europe into a global context, one 
can refer to the United Nations World drug report 2013 
(UNODC, 2013), which indicates that annual prevalence of 
cannabis use in Europe overall is above the global average 
but still below that of West and Central Africa (12.4 %), 
North America (10.7 %) and Oceania (10.9 %). However, 
there is considerable variation within Europe, with annual 
prevalence rates ranging from 0.3 % in Romania to 9.6 % in 
Spain. In terms of the demographics of the affected 
population, available data indicate that the typical cannabis 
user in Europe is a young male aged 15 to 24.
More than cannabis use as such, problematic use of the 
drug is highly relevant for the healthcare sector and 
policymakers. Data on regular use of cannabis, available 
from population surveys, can be used as an indicator of 
the prevalence of such problematic patterns of use in the 
population. Thanki et al. (2012) provided an overview on 
the prevalence of daily or almost daily cannabis use, 
defined as use on 20 or more days in the month prior to 
the survey. Results were based on self-reported data from 
large, probabilistic, nationally representative samples of 
the general population. The countries included represent 
more than 83 % of the population of the European Union 
and Norway. In these countries, between 3.5 % and 44 % 
of last-month cannabis users reported daily or near-daily 
use — an overall proportion of 25 %. The prevalence of 
daily or near-daily use in the adult population (15–64 
years) ranged from 0.05 % to 2.6 % for these countries, 
resulting in an overall rate of 1 %. This equates to 3 million 
people who consume cannabis daily or almost daily. 
However, this must be considered a minimum estimate 
because of the possibility of under-reporting among 
survey participants and the higher probability of frequent 
users occurring outside the sampling frame of general 
population surveys. About two-thirds of daily or near-daily 
users are between 15 and 34 years old and three-quarters 
are male (EMCDDA, 2013a).
Cannabis problems are not driven only by the demand 
side; the supply side also plays a crucial role in these 
developments. Today, in the European Union, cannabis is 
predominantly consumed in two different forms: herbal 
cannabis (marijuana) and cannabis resin (hashish). 
Historically, cannabis resin was the most widely 
consumed cannabis product in western European 
countries (EMCDDA, 2012a). Over the past decade, 
there has been a major shift across Europe from the use 
of cannabis resin to the use of herbal cannabis products, 
partly driven by an increase in domestic production in 
the European Union. Today, herbal cannabis is the most 
used cannabis product in Europe overall. Cannabis resin 
remains the most widely used cannabis product only in 
countries in the south-west and north of Europe. Even in 
these countries, however, its use has declined 
considerably relative to that of herbal cannabis products.
In addition to cannabis resin and herbal cannabis, 
synthetic cannabinoids play a small, but possibly 
increasing, role in consumption. These synthetic 
substances bind to cannabinoid receptors in the central 
nervous system, producing similar effects to cannabis. 
They constitute a relatively new cannabis-like product, 
which is now available in most EU countries, and often less 
controlled than cannabis. Given the often higher potency 
and chemical differences of these substances, there may 
be specific risks different from those known for cannabis.
I  Health consequences of cannabis use
Although cannabis has historically been viewed as much 
less harmful than so-called ‘hard drugs’, such as opioids 
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the share of cannabis-dependent users who seek help is 
the lowest for any illicit drug (Stephens et al., 2007). 
Perceived barriers to treatment include not being aware 
of treatment options, thinking treatment is unnecessary, 
not wanting to stop using cannabis and wanting to avoid 
the stigma associated with accessing treatment (Gates 
et al., 2012).
I  Trends in treatment provision for cannabis-related problems
The widespread use of cannabis across the European 
Union and the increase in the use of the drug over many 
years is reflected in the high number of cannabis users 
now seeking treatment. In 2012, 110 000 of those 
enrolling in specialised drug treatment in the European 
Union reported cannabis as the primary drug for which 
treatment was being sought (Table TDI-062 in EMCDDA, 
2014a). Cannabis is the second most commonly 
reported primary drug in both inpatient (18 % of clients) 
and outpatient (26 % of clients) treatment settings 
(Tables TDI-050 and TDI-056 in EMCDDA, 2014a). All 
countries report admitting cannabis users for treatment 
in outpatient settings, and most countries also report 
cannabis users entering treatment in inpatient settings. 
Primary cannabis users account for more than 30 % of 
treatment entrants in Belgium, Denmark, Germany, 
France, Cyprus, Hungary, the Netherlands and Poland, 
for less than 10 % in Bulgaria, Estonia and Malta, and for 
between 10 % and 30 % in the remaining EU Member 
and cocaine, the evidence indicates that cannabis may 
have serious health implications for some users.
A brief report compiled in 2011 by the US National 
Institute on Drug Abuse (NIDA) lists the main findings of 
research into the effects of cannabis on humans. 
Cannabis intoxication can negatively affect short-term 
memory, reduce reaction time and motor coordination, 
and impair judgement. Moreover, these cognitive and 
neurological impairments associated with cannabis 
intoxication could lead to risky behaviour (e.g. 
unprotected sex, driving while intoxicated). Consumption 
of high doses of cannabis can result in anxiety disorders 
and paranoia, or increase the risk of heart attack in 
vulnerable individuals. Long-term negative outcomes 
associated with cannabis use include dependence, 
poorer achievement-related outcomes, diminished life 
satisfaction, upper respiratory problems and increased 
risk of developing psychosis in vulnerable individuals. 
Cannabis dependence is a mental disorder with a 
distressing, chronic and relapsing nature.
In clinical settings, many cannabis users have been 
described as self-medicating for anxiety and depressive 
subclinical syndromes (anxiety, irritability, negative 
mood, physical symptoms and decreased appetite) 
(Weinstein et al., 2010). Individuals with cannabis 
dependence have been found to be six times more likely 
to have mood or anxiety disorders than those without 
cannabis dependence (Stinson et al., 2006). There is 
strong evidence from well-controlled prospective 
longitudinal studies for an association between 
cannabis use and increased risk of psychotic disorders 
(Moore et al., 2007), and specific genetic factors are 
emerging as plausible explanations for increased risk 
among a subgroup of users (van Winkel, 2011; Verweij et 
al., 2010). There is consistent evidence that cannabis use 
is correlated with poor clinical outcomes, relapse, 
remission and exacerbation of symptoms across many 
psychiatric disorders (Baker et al., 2010). A more recent 
study also points towards long-term negative effects for 
intellectual development if the drug is used regularly 
during adolescence (Meier et al., 2012). Others have 
pointed out that these associations may not necessarily 
be the result of the direct effects of cannabis use 
(Danovitch and Gorelick, 2012).
Although only a small proportion of intensive users may 
develop cannabis-related health problems, because of 
the non-trivial prevalence of intensive cannabis use 
within populations large numbers of people may develop 
such problems, making it a public health problem of 
some size (Copeland and Swift, 2009). Compared with 
users of other drugs, cannabis users are less likely to 
seek help for their drug problems. At an estimated 10 %, 
FIGURE 1
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explained by differences in the prevalence of use. Factors 
at national level may also influence the numbers entering 
treatment. Among these are the following: the proportion 
of users developing problematic patterns of use; the 
perceived risk and harm of cannabis use at population 
level and related policy decisions; differences in funding 
of treatment provision; and referrals for treatment from 
the criminal justice system. In addition, the availability, 
quality and price of cannabis products on the national 
market may have indirect effects on treatment needs and 
requests. Other factors influencing availability of 
treatment include funding mechanisms in the country, 
treatment systems and treatment organisation.
How the provision of treatment for cannabis-related 
problems relates to treatment needs is an important 
question for policymakers. Scientific findings have shown 
the existence of problematic acute and long-term effects 
of cannabis use. Some of these may be permanent, 
especially in the case of users who are adolescents or 
children. Cannabis-related problems are correlated with 
other mental health problems, and although causal or 
multiplying effects of the drug often remain unclear, they 
cannot be excluded. While a smaller percentage of 
cannabis users than users of other illicit drugs, such as 
heroin, seek treatment, the overall high prevalence of use 
results in a considerable number of cases where 
treatment is needed. This has clear implications from a 
public health perspective. Furthermore, the debate in 
some countries about decriminalisation of or changes in 
the regulations on cannabis consumption calls for 
reflection on the possible effects on treatment needs. 
While the impact that possible changes in the law may 
have on the use of cannabis is outside the scope of this 
publication, the need for evidence-based interventions for 
problematic users will continue.
States. The number entering treatment for the first time 
in their life is commonly used as an indicator of trends in 
treatment demand. Between 2006 and 2012, the 
number of cannabis users entering treatment for the first 
time in their life has increased, whereas first-time 
treatment admissions for heroin and cocaine have 
declined. Among first-time entrants to drug treatment, 
cannabis is now the primary substance most frequently 
reported (Figure 1).
I  Treatment needs and  cannabis-related problems
The upward trend in the number of cannabis users 
entering drug treatment in Europe is no longer in step 
with the trend in prevalence of cannabis use among the 
general population. After many years of signalling 
increasing cannabis use, prevalence indicators now 
point to use of the drug having levelled off or, in some 
countries, gone into decline. The continued upward trend 
in treatment demand may reflect the delay typically 
observed between the onset of drug use, the 
development of harmful patterns of use and associated 
problems, and referral for treatment. The average 
cannabis user entering treatment in Europe is 26 years 
old and first used the drug at age 16. The overall trends 
may hide differences between different user groups. One 
possible scenario is that the prevalence of problem 
forms of cannabis use may still be on the increase while 
less problematic patterns of use are decreasing.
Overall, there is considerable regional variation in the 
prevalence of cannabis treatment, which cannot be 
A search strategy was carried out to identify all relevant systematic reviews, narrative reviews and individual 
studies (randomised controlled trials and observational studies) on the effectiveness of treatment for cannabis 
users (adolescents or adults) published after 2008. Publications in three databases (PubMed, EBSCO and Google 
Scholar) were searched using the following search terms: cannabis, marijuana, treatment, therapy, counselling, 
evaluation, efficacy and effectiveness. Publications were selected for further inspection if at least one treatment 
approach was evaluated which was also used for treatment of cannabis use disorders, or if the study revealed 
relevant information concerning the factors which influence the effectiveness or the acceptability of these 
treatments. Studies focusing only on alcohol or tobacco were excluded. The results were summarised and 
compared with an earlier work on the same topic published in an EMCDDA monograph (Bergmark, 2008).
Data presented in this report regarding cannabis-specific treatment programmes in Europe were also obtained 
from a number of EMCDDA sources, provided either directly or indirectly through the Reitox network, made up of 
Methods and sources of data
Treatment of cannabis-related disorders in Europe
16
national focal points in the 28 EU Member States, Turkey and Norway. The sources were as follows: EMCDDA 
Annual reports from 2008 to 2012; Reitox national reports to the EMCDDA from 2008 to 2012; Exchange on Drug 
Demand Reduction Action (EDDRA) online resources; the cannabis treatment section of Structured 
Questionnaire 27 (SQ27); the Cannabis-Specific Treatment National Focal Point Survey (CSTNFPS); 
and the Cannabis-Specific Treatment Programme Manager Survey (CSTPMS).
The EMCDDA Annual reports provided a yearly assessment of the drug problem in Europe, containing facts and 
figures on drug policy, use, trafficking and treatment in the 28 EU Member States, Turkey and Norway. The 2012 
report was the most recent one available when the data for the current publication were collected. In 2013, the 
Annual report was succeeded by the European Drug Report.
Each year, Reitox national focal points provide the EMCDDA with a report detailing the drug phenomenon on a 
national basis.
The EDDRA online resources contain additional information on cannabis-specific treatment options  
(accessible at emcdda.europa.eu/themes/best-practice/examples).
The SQ27 is a routine data collection via a structured questionnaire that was last updated by the EMCDDA in 
2011. The structured questionnaire addresses the policies and interventions that EU Member States, Turkey and 
Norway have established to provide evidence-based drug treatment; it also gathers information on measures that 
countries have taken to achieve and maintain a high quality of treatment service provision. The survey was sent to 
each national focal point. Of the 30 national focal points contacted to participate in this survey, 29 completed the 
survey (response rate 97 %). The survey included items assessing basic information about cannabis-specific 
treatment programmes offered in each country.
The CSTNFPS was a 15-item survey created and administered by the authors of this report in February 2013.  
The purpose of this survey was to gather basic data about currently available inpatient and outpatient cannabis-
specific treatment programmes offered in European countries. The survey contained items assessing the 
following information: presence of cannabis-specific treatment programmes in the country, name of the 
programme, average waiting time for treatment, cost of treatment to participants, percentage of people in need 
who receive treatment, presence of cannabis-specific programmes for adolescents, sources of referral for the 
available programmes, and additional information regarding national cannabis use disorder treatment 
programmes. Of the 30 national focal points contacted to participate in this survey, 19 completed the survey 
(response rate 63 %).
The CSTPMS was a six-item survey created and administered by the authors of this report in March 2013. This 
survey was sent to managers of cannabis-specific treatment programmes who were identified by national focal 
points in the CSTNFPS. The survey contained items assessing the following information: name of the programme, 
description of the programme, standard dose of treatment, status of empirical evidence regarding the efficacy or 
effectiveness of the programme, and references to studies indicating efficacy or effectiveness. Of the 14 
programme managers that were contacted to participate in the survey, nine, representing five countries and 10 
different programmes, completed the survey (response rate 64 %). The purpose of this survey was to provide 
detailed information on individual cannabis-specific interventions.
The CSTNFPS and the CSTPMS were the primary sources of data used to characterise European cannabis-
specific interventions in this report. For Member States that did not complete one of these surveys, data from one 
or more of the following sources were used: online resources, literature review, SQ27.
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needs of cannabis users. In addition, group therapy 
interventions incorporated into cannabis-specific 
programmes may be more effective, as group members 
may benefit from an increased universality of experience 
in their interactions. In other words, since group 
members in these interventions engage in problematic 
use of the same substance, they may be better able to 
relate to each other’s substance-related experiences 
and behaviours. Another advantage of cannabis-specific 
programmes over general substance use treatment 
programmes may lie in the reduced risk of typically 
younger, less problematic cannabis users mixing with 
more problematic, older users of other illicit substances.
General substance use treatment programmes may, 
however, offer some practical advantages over 
substance-specific approaches. General substance use 
treatment may be more cost-effective and easier to 
administer than separate programmes for a variety of 
substances. In addition, many of the demographic 
differences between cannabis users and users of other 
substances could be addressed by tailoring treatment to 
specific age groups or target populations, rather than 
specific substances. Alternatively, general substance 
use treatment services could be tailored to individual 
needs on a case-by-case basis. Finally, in support of 
general substance use treatment approaches, 
epidemiological and clinical literature indicates that the 
symptoms of cannabis dependence are similar to the 
symptoms of dependence on other substances (Budney, 
2006). Moreover, the reasons given by cannabis users 
for seeking treatment and the treatment outcomes are 
similar to those for users of other substances (Dennis et 
al., 2002; McRae et al., 2003; Stephens et al., 1993).
EU Member States have taken different approaches to 
addressing cannabis treatment. The normal standard of 
care in the European Union has historically been general 
substance use treatment. Thus, general treatment 
programmes are widely available throughout the 
European Union, whereas only 15 of the 30 countries 
reporting to the EMCDDA currently offer treatments that 
are specific to cannabis.
Both general and specific approaches to treating 
cannabis-related problems exist and have been applied 
to meet the needs of people with cannabis-related 
disorders. The present publication evaluates both types 
of intervention. Programmes focused on cannabis 
problems are relatively recent additions to the array of 
drug treatment interventions available in Europe, and 
providing for the first time an EU-level overview of this 
class of treatment is one of the main aims of this 
publication. In the section ‘Estimation of unmet 
treatment needs’, Chapter 4, which compares indicators 
I  Delivery of treatment in Europe
Although subsidised national treatment programmes are 
common, there is no one treatment or intervention for 
cannabis use problems that is implemented in all 
Member States. Indeed, treatment for cannabis-related 
problems takes many forms across the European Union. 
Both evidence-based and non-evidence-based 
treatments are provided in Europe. In addition, treatment 
is offered in individual, group and family sessions and 
over the Internet. Treatment programmes are 
administered primarily in outpatient settings, although 
also in inpatient settings. Finally, treatment is 
administered by a variety of different service providers, 
including professionals (e.g. psychiatrists, 
psychologists), para-professionals (e.g. trained 
counsellors with other professional backgrounds) and 
laypeople (e.g. teachers and other individuals who work 
closely with at-risk individuals). Given the variety of 
treatment options currently available in the European 
Union, a major goal of the present report is to 
characterise the treatment of cannabis use disorders in 
Europe by providing in-depth, up-to-date information 
about the type and availability of treatments.
Although there is considerable diversity with regard to 
treatment approach for cannabis use disorders in the 
European Union, all treatment programmes can be 
roughly classified into one of two categories: cannabis-
specific treatment and general substance use treatment. 
Cannabis-specific treatment programmes treat only 
those individuals with cannabis-related problems. 
Typically, such programmes use interventions that are 
designed for or tailored to the specific needs of this 
population. In contrast, general substance use treatment 
programmes treat individuals with cannabis-related 
problems alongside individuals with problems related to 
other drugs. Treatment is typically administered by the 
same service providers and involves the use of general, 
non-specific substance use or dependence 
interventions. Although general substance use treatment 
has historically been the typical form of care in the 
European Union, the term is not synonymous with 
consensus-based treatment as usual. In fact, many 
countries offer general substance use treatment 
programmes that incorporate evidence-based 
interventions. For example, in the United Kingdom, 
individuals with cannabis-related problems are offered 
general substance use treatment programmes that are 
based on cognitive behavioural interventions.
Both substance-specific and general treatment 
approaches for cannabis-related problems have 
advantages and disadvantages. Cannabis-specific 
programmes are designed to meet the specific service 
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sure that sessions occur on the clinician  
(Godley et al., 2006).
I Behavioural family therapy
Behavioural family therapy (BFT) is aimed at helping 
families going through difficulties in their relationships. 
This group treatment is learning-based and, thus, applies 
cognitive behavioural analysis of the problems presented 
by a family. It focuses on changing thought patterns and 
overt behaviour (Psychology Dictionary, no date).
I Brief strategic family therapy
Brief strategic family therapy (BSFT) is a brief 
intervention used to treat adolescent drug use that 
co-occurs with other problem behaviours. These 
co-occurring problem behaviours include conduct 
problems at home and at school, oppositional behaviour, 
delinquency, associating with antisocial peers, 
aggressive and violent behaviour and risky sexual 
behaviour (Szapocznik et al., 2003).
I Cognitive behavioural therapy
Cognitive behavioural therapy (CBT) is a 
psychotherapeutic treatment modality offered in 
individual or group format (Butler et al., 2006). It is 
empirically supported as a treatment for substance  
use disorders and has been shown to be effective 
in studies containing samples of primary cannabis  
users.
In general, CBT involves challenging irrational, negative 
thinking styles, which are thought to promote negative 
affective states, which in turn promote maladaptive 
of treatment needs with estimated provision of 
treatment for this target group, general substance use 
approaches are also included.
I  Psychosocial approaches used to treat drug-related problems
The term ‘psychosocial approaches’ covers all forms of 
structured psychological or social interventions that may 
be used to treat substance-related problems. In the 
studies identified by this review, these approaches 
include a variety of different programmes and concepts. 
Most interventions followed either an individual-centred 
approach or a family approach (summarised in Table 1). 
They differ considerably in their level of detail and 
theoretical basis. A more theoretical overview of 
addiction and its treatment can be found in Robert 
West’s Models of addiction (EMCDDA, 2013b).
The main approaches are listed below, providing 
information on background, concept and practical 
application. It should be noted that the list is incomplete 
and the description of interventions is not theory-driven. 
Different approaches may share common techniques or 
be applied to the same target population. They 
approaches are listed alphabetically, to serve as a type 
of glossary when reading the outcome tables 
(Tables 3–6).
I Assertive continuing care
Assertive continuing care (ACC) is one of several 
‘assertive’ interventions available to treat substance 
use disorders. This approach aims to increase retention 
in treatment by placing the responsibility of making 
TABLE 1
Interventions for families and individuals
Target group Intervention (acronym)
Family Behavioural family therapy (BFT)
Brief strategic family therapy (BSFT)
Family process-only condition (FAM)
Functional family therapy (FFT)
Multidimensional family therapy (MDFT)
Multisystemic therapy (MST)
Structural ecosystems therapy (SET) 
Individuals (adolescents or adults) Assertive continuing care (ACC)
Cognitive behavioural therapy (CBT)
Contingency management (CM)
Drug counselling (DC)
Educational feedback (EF)
Motivational interviewing and motivational enhancement therapy (MI/MET)
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I Functional family therapy
Functional family therapy (FFT) is a short-term, high-
quality intervention programme with an average of 12 
sessions over a 3- to 4-month period. Services are 
delivered in both clinical and home settings, and can 
also be provided in a variety of other settings, including 
schools, child welfare facilities, probation and parole 
offices/aftercare systems and mental health facilities 
(Functional Family Therapy, no date).
I Multidimensional family therapy
Multidimensional family therapy (MDFT) (Liddle et al., 
2001) is a family systems-oriented outpatient 
intervention for adolescents and young adults. It is 
empirically supported as an effective treatment for 
cannabis use disorders. The intervention is designed to 
address problem cannabis use at four different levels:  
(1) the adolescent, (2) the adolescent’s parents, (3) the 
adolescent’s family, and (4) the adolescent’s extra-
familial network, which includes friends and peers in 
school, work and leisure settings. The principle 
underlying MDFT is that the family is instrumental in 
treating problem cannabis use by helping the adolescent 
to create new, developmentally adaptive lifestyle 
alternatives. Thus, interventions are aimed at improving 
family functioning, communication and accountability.
I  Motivational interviewing and motivational enhancement therapy
Motivational interviewing (MI) (Miller, 1983; Miller and 
Rollnick, 1991) is a therapeutic intervention typically 
offered in an individual therapy format. Since the focus 
of MI is to harness an individual’s motivation to engage 
in the treatment process, interventions based on MI are 
often employed at the initial phase of substance use 
treatment to motivate the client to engage in the more 
intensive psychosocial treatments, which are skills-
oriented (e.g. CBT). Motivational enhancement therapy 
(MET) relies heavily on the principles of MI. As these two 
concepts are strongly interrelated, they will be discussed 
together here and abbreviated as MI/MET.
MI/MET is empirically supported for substance use 
disorders and has shown to be effective for both adults 
and adolescents. MI/MET combines the 
transtheoretical model (Prochaska and DiClemente, 
1982) with client-centred therapy and self-efficacy. It is 
particularly useful in treating individuals who are 
ambivalent about personal behavioural change, as is 
often the case with those presenting with cannabis use 
behaviours, such as problem cannabis use. In addition to 
helping clients develop new ways of thinking, CBT 
interventions promote the development of alternative 
coping skills and the implementation of behavioural 
strategies for reducing and eliminating problem 
behaviours such as illicit drug use.
CBT for substance-related disorders works by means of 
self-control training (e.g. stimulus control techniques), 
social and coping skills training and relapse prevention. 
When CBT is used to treat problem cannabis use 
specifically, initial treatment sessions often involve 
developing skills directly related to achieving and 
maintaining abstinence from cannabis. Later CBT 
sessions may focus on topics and skills indirectly related 
to maintaining abstinence.
I Contingency management
Contingency management (CM) is a type of treatment 
used in the mental health and substance use fields. 
Patients’ behaviours are rewarded (or, less often, 
punished) in line with treatment objectives and, 
generally, adherence to or failure to adhere to 
programme rules and regulations or their treatment plan 
(Griffith et al., 2000).
I Drug counselling
Drug counselling (DC), delivered on an individual basis, 
addresses the symptoms of the drug addiction and 
areas of impaired functioning that are related to it, and 
the content and structure of the client’s ongoing 
recovery programme (Mercer and Woody, 1999).
I Educational feedback
Educational feedback (EF) (as described in Walker et al., 
2011) involves two sessions with a counsellor delivering 
a PowerPoint presentation on current research and facts 
about cannabis. Based on questions elicited from the 
participating teenagers, clients are informed about the 
effects of cannabis on the body, sexual behaviour and 
pregnancy. Further topics could include the legalisation 
debate, legal issues, and cannabis and medicine.
I Family process-only condition
Family process-only condition (FAM) focuses exclusively 
on working with family members to modify within-family 
interactions (Robbins et al., 2008).
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relationships with his or her peer group and school and 
with the juvenile justice system. SET is intended to be 
delivered over 12–16 family therapy sessions (e.g. 
sessions conducted with multiple family members) and 
12 ecosystemic therapy sessions (e.g. sessions with 
family members and individuals from the family’s social 
ecology) (Robbins et al., 2008).
I  Control conditions
Studies on the effectiveness of interventions have to 
prove that a change in the behaviour or state of a person 
is due to the treatment condition. The general approach 
is to use control conditions for comparison, which do not 
include the specific measure under research. In the 
studies analysed here, the following interventions have 
been used as controls.
I Community service
Community service (CS) is a type of punishment that 
involves working for the community. CS is used as a 
control condition in some studies.
I Delayed feedback
Delayed feedback (DF) is the name given by Walker et 
al. (2011) to the intervention provided to the 
participants assigned to the control arm. Participants in 
the DF condition were not assessed until the 3-month 
follow-up.
I Delayed treatment control
Delayed treatment control (DTC) compares the effect  
of the intervention with no intervention during  
this period in the control arm. To motivate subjects  
to participate in such studies and for ethical reasons,  
the same treatment is then — at a later stage — 
provided to the control group. This design cannot  
control for the effects of positive expectations  
in the control arm.
I Intention-to-treat analysis
Intention-to-treat (ITT) analysis is a quality criterion for 
studies, whereby the outcome is calculated on the basis 
of those initially assigned to the intervention, whether 
they received the intervention or not.
problems. The primary goal of this treatment approach 
for cannabis use disorders is to explore and resolve 
ambivalence about cannabis use and facilitate and 
engage the client’s intrinsic motivation to change 
problem behaviour.
Thus, MI/MET differs from other substance use 
treatments in that its purpose is not to impart 
information or skills. In contrast, it emphasises exploring 
and reinforcing the client’s intrinsic motivation to engage 
in adaptive behaviours and refrain from addictive 
behaviours, while simultaneously supporting the client’s 
autonomy. Techniques employed by MI/MET therapists 
include asking open-ended questions, providing 
affirmations to the client, listening reflectively and 
summarising the client’s statements.
I Multisystemic therapy
Multisystemic therapy (MST) is an intensive family and 
community-based treatment that addresses the 
multiple determinants of serious antisocial behaviour in 
chronic, violent or substance-using male or female 
juvenile offenders, ages 12 to 17, at high risk of out-of-
home placement. The multisystemic approach views 
individuals as nested within a network of interconnected 
systems that encompass individual, family and extra-
familial (peer, school, neighbourhood) factors. 
Intervention may be necessary in any one or a 
combination of these systems. Treatment sessions 
occur primarily with caregivers and other involved 
adults to make changes in the youth’s environment that 
will in turn result in changes in the youth’s behaviour. 
Individual therapy with the youth is not a routine 
component of MST. The primary goals of MST 
programmes are to decrease rates of antisocial 
behaviour and other clinical problems, improve 
functioning (e.g. family relations, school performance) 
and promote behaviour change in the client’s natural 
environment (Episcenter, 2010).
I Structural ecosystems therapy
Structural ecosystems therapy (SET) is a manualised 
family- and ecological-based intervention for adolescent 
drug use (Robbins et al., 2003). The within-family 
components of SET are (a) joining with family members, 
(b) tracking and eliciting family interactions to assess 
family relationships, (c) reframing to create a context for 
behaviour change to occur, and (d) restructuring 
maladaptive family relationships. The ecological 
components of SET include assessment of and 
intervention in the adolescent’s and family’s 
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I Treatment as usual
Treatment as usual (TAU) is used in experimental 
studies as a control condition against which the effects 
of an intervention can be compared. Instead of 
specifying the treatment, in this case, the (new) form of 
treatment being tested is compared with the routine 
type of intervention.
2
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Overall, 65 studies were found that fulfilled the 
inclusion criteria: 26 were reviews, 9 of which included 
a meta-analysis. The majority (31) of the remaining 39 
individual studies were randomised controlled trials. 
As one meta-analysis and one randomised controlled 
study contributed information on effectiveness  
as well as on factors of influence, the total number  
of studies is smaller than the sum of all subgroups  
(see Table 2).
The studies were heterogeneous in terms of design. In 
most of the primary studies, subjects were randomly 
assigned to an active intervention and to a control 
condition for comparison. The control condition was 
either an alternative active intervention, a combination of 
interventions, treatment as usual or a delayed treatment 
control. Measures of substance use were provided 
through self-report or a combination of self-report and 
biochemical measures of substance use. Baseline 
measurements were made of study outcome variables 
including abstinence, quantity and frequency of 
cannabis use and other substance use, number and 
severity of use-related problems, DSM-IV (American 
Psychiatric Association, 2000) dependence symptoms 
and other problem behaviours. Studies generally 
reported following study participants for periods of 1 to 
12 months. Most studies provided information on loss of 
study participants over time, which is a common 
occurrence in clinical trials. The number of study 
dropouts was counted and a retention rate calculated. 
Methodologically strong studies included measures of 
quality assurance, for example using a manual to guide 
the intervention, providing some type of training and 
supervision of study counsellors and assessing 
treatment fidelity using audio or video recordings of the 
therapy sessions.
None of the 26 reviews identified were published by 
European research groups; the majority were from the 
United States or Australia. Only three of the 39 individual 
studies were European ones; these three looked at the 
effectiveness of cannabis-specific brief motivational 
enhancement for adolescent cannabis users 
(McCambridge et al., 2008) and the efficacy of MDFT for 
adolescents in the Netherlands (Hendriks et al., 2011) 
and Germany (Tossmann et al., 2012). The two later 
studies were part of the International Need of Cannabis 
Treatment (INCANT) collaboration.
CHAPTER 2
Effectiveness of interventions:  
review of recent research on  
available treatments
TABLE 2
Type and number of studies included in the review
Adolescents Adults Studies on 
tele-interventions
Factors 
influencing 
effectiveness 
of treatment
Total
General 
substance 
use treatment 
programmes
Cannabis-
specific 
treatment 
programmes
General 
substance 
use treatment 
programmes
Cannabis-
specific 
treatment 
programmes
Meta-analyses 3 1 4  0  1  1 (3) 9
Reviews 7 1 1  5  1  2 17
Randomised controlled 
trials
4 6 3  5  8  6 (3) 31
Quasi-experimental 
study and observational 
studies
3 0 0  1 (1)  2 (2)  2 (2) 8
Total 17 8 8 11 12 11 65
(1) Pre/post, (2) observational, (3) one study also listed under ‘Adults’.
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significant for both groups, but between-group 
differences had disappeared. Two further randomised 
controlled trials did not find significant treatment effects 
for a school-based MI intervention for adolescent 
cannabis users (McCambridge et al., 2008; Walker et al., 
2011). Both of these studies compared the effectiveness 
of a single session of MI against drug information and 
advice in reducing cannabis use.
Given that each treatment approach has specific 
strengths and limitations, clinical researchers have 
begun to combine different treatments in efforts to 
increase overall effectiveness. The most common 
approach is a combination of elements designed to 
strengthen clients’ motivation to change (MI, MET) and 
elements targeting thoughts, emotions and behaviours 
that are implicated in substance use (CBT). Researchers 
have also evaluated whether CM adds to the efficacy of 
combined treatment interventions.
Martin and Copeland (2008) conducted a randomised 
controlled trial examining the effectiveness of a two-
session CBT and MI combination treatment compared 
with a 3-month delayed treatment control condition in a 
sample of 40 people aged between 14 and 19 years. 
They found that, compared with the control condition, 
MI/CBT produced significantly greater reductions in the 
frequency of cannabis use per week, the quantity of 
cannabis used per week and the number of DSM-IV 
dependence symptoms at the 3-month follow-up.
Stanger et al. (2009) found that an additional element of 
CM improves the efficacy of MET/CBT interventions. In 
the study, 69 adolescents were randomly assigned to 
one of two groups, both of which received MET/CBT and 
a twice-weekly drug-testing programme. Both groups 
additionally took part in an incentive programme (i.e. CM 
intervention). In the experimental condition, incentives 
were abstinence-based, whereas incentives were 
attendance-based in the control group. Results revealed 
that cannabis abstinence was significantly greater in the 
experimental condition during treatment. After 
treatment, cannabis use tended to rise, but at 9 months 
it stabilised at a level lower than baseline.
The CANDIS study, by Hoch et al. (2012), tested the 
effectiveness of a programme for cannabis use disorders 
that blends aspects of CBT and MI in a sample of 122 
participants over the age of 16 years who had been 
diagnosed with cannabis dependence. Subgroup 
analyses showed that teenagers could benefit from the 
programme, and abstinence rates at the end of treatment 
were comparable between them and the adult subgroup 
in the study. More details on the study can be found in 
Table 5, as the study focused on an adult target group.
I  Research on treatment for adolescents
The literature on the effectiveness of treatment for 
adolescents is considerably less developed than the 
corresponding literature on adults, but recent empirical 
studies have begun to provide more insight into the 
effectiveness of cannabis-specific treatment in this 
population.
Overall, the search strategy identified 25 publications on 
interventions for adolescent cannabis users.
Eight publications were about cannabis-specific 
treatment for adolescents with cannabis use disorders: 
one meta-analysis (Bender et al., 2010), one literature 
review (Copeland and Swift, 2009) and six randomised 
controlled trials (Hendriks et al., 2011; Martin and 
Copeland, 2008; McCambridge et al., 2008; Stanger et 
al., 2009; Tossmann et al., 2012; Walker et al., 2011).
Seventeen publications addressed adolescent cannabis 
users in general substance use treatment programmes. 
Among these publications, there were three meta-
analytical reviews (Baldwin et al., 2012; Jensen et al., 
2011; Tanner-Smith et al., 2013), seven literature reviews 
(Barnett et al., 2012; Becker and Curry, 2008; Griffin and 
Botvin, 2010; Hogue and Liddle, 2009; Macgowan and 
Engle, 2010; Rowe, 2012; Waldron and Turner, 2008), 
three randomised controlled trials (Godley et al., 2011; 
Liddle et al., 2008; Robbins et al., 2011), one 
effectiveness trial (Letourneau et al., 2009), two 
observational studies (Lott and Jencius, 2009; 
Ramchand et al., 2011) and one quasi-experimental 
study (Hunter et al., 2012).
I Cannabis-specific treatment for adolescents
Interventions targeting the individual
We identified six randomised controlled trials (involving 
905 participants) performing various combinations of 
MI/MET, CBT and CM (Table 3).
Two studies provide information on MI/MET applied 
alone without further treatment elements. Walker et al. 
(2011) compared MET with an ‘educational feedback 
control’ intervention and a delayed feedback control 
group. The study was conducted on 310 cannabis users 
aged 14 to 19 years old, who were assigned to one of the 
three groups. At the 3-month follow-up, both active 
treatments showed significant reductions in cannabis 
use, with participants in the motivational enhancement 
condition showing greater reductions. After 12 months, 
reductions in use and use-related problems were still 
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al., 2001). Bergmark concluded that the treatment 
modality has less impact on treatment outcome than the 
context in which treatment is delivered and the 
individual’s motivation to engage in treatment.
I General treatment of substance use disorders
Interventions targeting the individual
Among the reviews addressing treatments for 
adolescent substance use in general, we identified 17 
publications, 7 of which are narrative reviews, including 
143 studies, and 3 are meta-analyses, including 90 
studies (see Table 4).
Findings show that most treatments that aim to reduce 
substance use appear to be beneficial for adolescents. 
Although Waldron and Turner (2008) found no clear 
differences in effectiveness between the treatment 
approaches, behaviour-based interventions emerged as 
‘well-established’ (Waldron and Turner, 2008) or 
‘probably efficacious’ (Macgowan and Engle, 2010), or 
showed evidence of immediate superiority (Becker and 
Curry, 2008). Motivational interventions were found to 
be ‘promising’ (Macgowan and Engle, 2010), or also 
showed evidence of immediate superiority (Becker and 
Curry, 2008).
Jensen et al. (2011) conducted a meta-analysis (5 471 
participants, 21 studies) to determine the effectiveness 
of MI interventions on adolescent substance use. Their 
results revealed that MI interventions have a small yet 
significant effect on substance use at both post-
treatment and follow-up assessments. These results 
suggest that adolescent substance users treated with MI 
interventions can make significant gains in treatment 
and maintain these gains even after treatment has 
ended.
Barnett et al. (2012) conducted a systematic review of 
39 studies, conducted between 1998 and 2011, 
examining the effectiveness of MI on substance use. 
They found that two-thirds of the studies reported a 
statistically significant reduction in substance use. No 
significant differences were found between motivational 
interventions that used feedback and those that did not 
use feedback. In addition, their review included seven 
randomised controlled trials that focused specifically on 
the treatment of cannabis use with MI. Of these seven 
studies, five found significant effects for the MI 
intervention compared with control conditions, including 
a study that found that MET reduced cannabis use at 
post-treatment, 3-month and 12-month follow-up 
assessments.
Copeland and Swift (2009) concluded that brief CBT 
treatment approaches have the most empirical support; 
however, they found that CM (e.g. monetary reward for 
abstinence) and family-systems approaches may be 
particularly effective adjunctive treatment options for 
adolescents.
Family-based interventions
Studies examining the effectiveness of family-based 
interventions on cannabis use are scarce. The few 
studies available suggest that family-based 
interventions are effective approaches for treating 
cannabis disorders in adolescents. We identified one 
meta-analysis of 15 randomised controlled evaluations 
of interventions to reduce adolescent cannabis use 
published between 1960 and 2008 (Bender et al., 
2010), one review (Copeland and Swift, 2009); and two 
RCTs involving 229 patients between 13 and 18 years 
of age.
Hendriks et al. (2011) compared the effectiveness of 
MDFT and CBT for treatment of cannabis use disorders 
in a randomised trial. They found that both interventions 
were equally effective in reducing cannabis use in a 
sample of adolescents from the Netherlands. In a 
German sample, Tossmann et al. (2012) compared the 
effectiveness of MDFT and an individual therapy 
combining elements of CBT and MET in the treatment of 
cannabis use disorders. The results revealed that MDFT 
was significantly more effective than CBT in reducing 
cannabis use.
These results are consistent with a previous review for 
the EMCDDA by Bergmark (2008), which reviewed 
results from the Cannabis Youth Treatment Study 
(Dennis et al., 2004), a large (600 participants), 
randomised, multisite trial comparing the effectiveness 
of five different cannabis treatment conditions: five 
sessions of MET and CBT, 12 sessions of MET and CBT, 
family support network, the adolescent community 
reinforcement approach and MDFT. The results of the 
study revealed that treatment outcomes were very 
similar across sites and conditions; however, a 
combination of MET and CBT emerged as the most 
cost-effective treatment. In addition, Bergmark (2008) 
found that research concerning the effectiveness of 
family-based substance use treatment produced mixed 
results. While some of the studies included in his review 
found strong support for the effectiveness of family-
based treatments (Ozechowski and Liddle, 2000; 
Prendergast et al., 2002; Stanton and Shadish, 1997; 
Williams and Chang, 2000), others reported 
contradictory findings (Dennis et al., 2004; Waldron et 
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however, family-based interventions were found to be 
more effective than comparison treatment conditions. 
Becker and Curry (2008) found evidence of ‘immediate 
superiority’ for ecological family therapy. Waldron and 
Turner (2008) regarded MDFT and functional family 
therapy as ‘well-established’, and brief strategic family 
therapy, behavioural family therapy and multisystemic 
therapy as ‘probably efficacious’ models for substance 
use treatment.
Baldwin et al. (2012) concluded from their meta-analysis 
of four studies that family-based interventions (e.g. brief 
strategic family therapy, functional family therapy, MDFT, 
or multisystemic therapy) had statistically significant, 
but modest, effects compared with alternative 
treatments for substance use. Interestingly, the authors 
observed larger, but insignificant, effects when 
comparing family-based treatments with no-treatment 
control groups. The authors concluded that this counter-
intuitive result was likely to have resulted from 
underpowered analyses of these comparisons. In 
addition, the meta-analysis did not have enough power 
to determine if different family-based approaches had 
different levels of effectiveness.
Some recent research has focused on the effects of brief 
strategic family therapy (BSFT) on adolescent 
substance use. Griffin and Botvin (2010) found in their 
review of effectiveness literature that treatment with 
brief strategic family therapy (including eight studies) 
produced significant pre–post reductions in cannabis 
use, and other substance use, compared with a no-
treatment control group in one study. However, 
compared with treatment as usual (i.e. standard 
treatment offered at community mental health centres), 
brief strategic family therapy was not found to be 
significantly more effective in reducing adolescent 
substance use in a recent individual randomised 
controlled trial including 471 adolescents (Robbins et al., 
2011).
Multidimensional family therapy (Liddle et al., 2001), 
another family-based treatment approach, has also 
received some empirical support. Liddle et al. (2008) 
compared the effectiveness of MDFT and a peer group 
intervention with young teens (mean age 13.7 years) in a 
randomised controlled trial recruiting 83 patients. From 
the beginning of treatment until the last follow-up 
assessment at 12 months, MDFT showed superior 
effectiveness in reducing substance use frequency and 
substance use problems. EMCDDA (2014c) conducted a 
systematic review of literature comparing MDFT with 
other treatments for adolescent substance use 
(including five studies). They concluded that MDFT is an 
empirically supported intervention for substance use 
In an observational study, Ramchand et al. (2011) 
compared the effectiveness of community-based 
outpatient treatment and MET combined with five 
sessions of CBT (MET/CBT5) in a sample of 605 
adolescents (mean age 15.7 years) meeting at least one 
of the criteria of abuse or dependence (DSM-IV-TR; 
American Psychiatric Association, 2000). Adolescents 
receiving the MET/CBT5 condition exhibited greater 
reductions in substance use frequency, substance use 
problems and illegal behaviours 12 months after 
treatment entry than those allocated to a community-
based outpatient treatment.
A second quasi-experimental study by the same 
research team administered the same CBT/MET 
combination treatment in a community practice setting 
(involving 2 751 adolescents) and replicated the findings 
from the previous study (Hunter et al., 2012). 
Furthermore, under these better-controlled conditions, it 
showed that participants receiving MET/CBT5 had 
better results at the 12-month evaluation than the 
control group.
Godley, S., et al. (2010) compared a MET/CBT 7-session 
intervention with another outpatient treatment 
(Chestnut’s Bloomington outpatient treatment) in a 
sample of 320 adolescents. Both interventions 
significantly reduced cannabis use over 12 months; 
however, the MET/CBT combination was more cost-
effective.
In community-based treatment studies with samples of 
polysubstance users, results on the effectiveness of CM 
were mixed. Lott and Jencius (2009) found that 
adolescents participating in a CM programme had 
significantly lower rates of positive opioid and cocaine 
urine samples than adolescents treated without CM. 
However, no significant differences were found for all 
other drug classes, including cannabis, although rates 
were trending lower in adolescents treated with CM.
Family-based interventions
Although studies on the effectiveness of family-based 
general substance use treatment interventions on 
cannabis use are scarce, there is some evidence that the 
family-based intervention is an effective approach for 
treating general substance use in adolescents. In 
particular, we identified two meta-analyses, five reviews 
and one RCT.
Comparing pre–post effect sizes, Tanner-Smith et al. 
(2013) found that adolescents in almost all treatment 
modalities showed reductions in substance use; 
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et al., 2012; Barnett et al., 2012; Becker and Curry, 2008; 
Griffin and Botvin, 2010; Hogue and Liddle, 2009; 
Jensen et al., 2011; Macgowan and Engle, 2010; Rowe, 
2012; Tanner-Smith et al., 2013; Waldron and Turner, 
2008). Positive treatment effects were shown for MET 
(Barnett et al., 2012; Becker and Curry, 2008; Jensen et 
al., 2011; Macgowan and Engle, 2010), CBT (Becker and 
Curry, 2008; Macgowan and Engle, 2010; Waldron and 
Turner, 2008), CM (Lott and Jencius, 2009) and various 
types of family interventions (Baldwin et al., 2012; 
Becker and Curry, 2008; Griffin and Botvin, 2010; Hogue 
and Liddle, 2009; Liddle et al., 2008; Rowe, 2012; 
Tanner-Smith et al., 2013; Waldron and Turner, 2008). 
Generally, abstinence was a less common outcome than 
reduction in the frequency of cannabis use.
I  Research on treatment for adults
A range of behaviour-based treatment options have been 
studied for the treatment of cannabis dependence. 
These include MET and a combination of CBT and CM. 
We reviewed the most recent studies on treatment 
options for cannabis dependence in adults, including 
interventions for those with co-occurring cannabis use 
and psychiatric symptoms.
I Cannabis-specific treatment for adults
For adults with cannabis use problems, no cannabis-
specific programmes were found targeting their families.
A small number of studies were found that target the 
adult population of people with cannabis-related 
disorders who also show co-occurring psychiatric 
problems. As this group shows specific needs and may 
differ from others with respect to effectiveness of 
interventions, it is presented separately in this section.
Interventions targeting the individual
Psychosocial approaches involving CBT, MI/MET or CM 
were investigated in 10 studies identified through the 
search strategy. In particular, Weinstein et al. (2010) 
examined whether CBT was effective in treating cannabis 
withdrawal syndrome in a sample of 26 individuals 
diagnosed with cannabis dependence. They found that 
only 20 % of the participants remained abstinent after 6 
months. The remainder of the participants either relapsed 
prior to the 6-month follow-up (30 %) or dropped out of 
the treatment programme prior to receiving the full 
12-week dose of CBT (50 %).
and that it is slightly superior to most other treatments 
(e.g. CBT, MET) in terms of treatment adherence and 
long-term maintenance of treatment gains. MDFT also 
appeared to be more effective in reducing severity of 
substance use and related problems than CBT; however, 
this conclusion was not supported for studies in which 
participants were being treated for cannabis use 
disorders. Thus, with regard to treatment for problem 
cannabis use, MDFT appears to be comparable to other 
evidence-based treatments. Finally, the authors argued 
that some of the benefits of MDFT may be attributable 
to a larger dose of treatment compared with brief 
interventions (e.g. MI, MET, CBT).
Multisystemic therapy has been classified as a ‘probably 
efficacious’ family-based treatment for substance use 
disorders in a review of 17 studies (Waldron and Turner, 
2008). Letourneau et al. (2009) compared multisystemic 
therapy in a sample of 127 juvenile sex offenders with 
services that are typically provided to this group in the 
United States. At the 12-month follow-up, young people 
in the multisystemic therapy condition exhibited 
significantly reduced substance use relative to the 
control group.
I Conclusions
Interventions for adolescents with cannabis use 
disorders address young people at early stages of their 
cannabis-using careers. They take into account a young 
person’s current risk behaviour and his or her general 
relationship to drugs, as well as associated physical, 
mental or psychosocial problems. Research on the 
efficacy of such interventions is still scarce compared 
with treatment studies of other child and adolescent 
disorders, such as anxiety, attention deficit hyperactivity 
disorder (ADHD) and depression (Gilvarry, 2000; Liddle 
et al., 2008). Nevertheless, this review of the current 
literature indicates that the knowledge base for treating 
children and adolescents with cannabis use problems is 
growing, albeit slowly. Among the studies reviewed here, 
more attention is given to general substance use 
treatment models that take into account the 
developmental stage and special needs of young people, 
rather than simply generalising (potentially age-
inappropriate) adult programmes to this group 
(Pumariega et al., 2004).
Findings from meta-analyses and RCTs indicate that 
adolescents with cannabis use problems generally 
benefit from various treatment approaches. Aggregated 
data from recently published meta-analyses and reviews 
provide strong evidence for the efficacy of treatments 
targeting adolescent substance use in general (Baldwin 
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I  General treatment of substance use disorders  in adults
As with the studies on adolescents, the search strategy 
identified a number of studies on substance use 
disorders in adults in which cannabis use may be 
involved, although not exclusively (see Table 6).
A large body of research exists on the effectiveness of 
CBT for the treatment of substance use disorders. To 
provide a quantitative summary of this research, Magill 
and Ray (2009) conducted a meta-analysis of 53 
randomised controlled trials examining the effectiveness 
of CBT in the treatment of adults diagnosed with alcohol 
or substance use disorders. The authors found a small, 
but statistically significant, effect of treatment. The 
effect of CBT was largest in cannabis studies, but 
tended to diminish over time. In addition, gender was 
found to be a potential moderating factor, making CBT 
more effective for women than for men.
A meta-analytical review of 34 randomised controlled 
studies of treatments for polysubstance use found that a 
combination of CBT and CM is the best approach for 
treating adult substance use disorders (Dutra et al., 
2008). However, this finding must be interpreted 
cautiously, as only two studies included in the meta-
analysis contained a condition in which a combination 
(CBT/CM) treatment was administered. Yonkers et al. 
(2012) examined the effectiveness of a CBT/MET 
combination treatment compared with brief advice 
about substance use from obstetricians in a sample of 
pregnant women with substance use disorders. No 
significant differences were observed between 
treatment groups, suggesting that in this population 
even brief treatments may be effective in reducing 
substance use. Consistently with these results, a brief 
intervention targeting risky behaviours associated with 
cannabis use was shown to reduce risky cannabis-
related behaviour (e.g. driving after cannabis use) in a 
sample of college students (Fischer et al., 2013).
There is also a large empirical literature on the 
effectiveness of MI-oriented approaches for the 
treatment of substance use disorders. Lundahl et al. 
(2010) conducted a meta-analysis of 119 treatment 
studies. MI was found to have a consistent small effect 
on substance use in general, and cannabis use 
specifically, compared with weak comparison groups 
(e.g. waiting list, written materials, non-specific 
treatment as usual). However, compared with a specific 
treatment, no significant effect for MI was observed, 
suggesting that its effects are equivalent to those of 
other specific treatments (e.g. CBT, 12-step). The 
authors concluded that MI may be more cost-effective, 
In a recent randomised controlled trial examining the 
effects of MI on cannabis use specifically, Stein, L., et al. 
(2011) found that MI was more effective in reduced 
cannabis use than an assessment control condition at 
the 3-month follow-up. These effects were not observed, 
however, at the 6-month follow-up, except for 
participants who entered the trial with a desire to 
abstain from cannabis use. This finding suggests that 
motivation to abstain from substance use when entering 
treatment may moderate treatment efficacy.
In an attempt to increase the effectiveness of cannabis 
use treatment for adults, combinations of various 
treatment approaches have been utilised. Similarly to 
the adolescent literature, the evidence suggests that the 
most effective combined treatment for adults is a 
combination of CBT, MI and CM.
In a randomised controlled clinical trial, Hoch et al. 
(2012) examined the effectiveness of CANDIS, a 
treatment programme for cannabis use disorders 
combining aspects of CBT and MI. A sample of 122 
patients diagnosed with cannabis dependence was 
randomly assigned to a 10-session CANDIS intervention, 
which consisted of MET, CBT and psychosocial problem-
solving training, or to a delayed treatment group. 
Analyses revealed that about half of the active treatment 
group achieved abstinence at post-treatment (49 %) and 
maintained abstinence at the 6-month follow-up (45 %). 
In addition, compared with the control group, 
participants in the intervention condition exhibited 
significantly lower frequency of cannabis use, addiction 
severity, number of disability days and overall level of 
psychopathology.
When the effectiveness of CM, CBT/MET and CBT/
MET/CM was compared with a case management 
control condition in a randomised controlled trial, the 
CBT/MET/CM condition was found to be associated 
with the highest rates of cannabis abstinence at 
follow-up assessment for up to one year (Kadden and 
Litt, 2011).
These findings appear to be in contradiction with the 
outcome of Carroll et al. (2012), which compared the 
effectiveness of four different treatments for cannabis 
use (CBT alone, CM for abstinence alone, CBT with CM 
for homework completion, CBT with CM for abstinence) 
on a sample of 127 young adults, 94 % of whom were 
referred for treatment by the criminal justice system. 
Individuals in the combined treatment groups had worse 
outcomes (i.e. lower abstinence rates). The authors 
concluded that a combination of cannabis use 
treatments may not be effective in a population of 
individuals involved with the criminal justice system.
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mood disorders, Baker et al. (2010) concluded that 
effective cannabis treatment in this population requires 
longer or more intensive psychological interventions 
rather than brief interventions. Specifically, they argued 
that an intensive combination of CBT and MI is the most 
effective treatment approach.
When looking at general treatment, Cleary et al. (2009) 
concluded from their review of psychosocial treatments 
for individuals with substance use disorders and 
co-morbid severe mental illness that a combination of 
CBT and MI was most effective (Table 6). Specifically, 
they found that a combination of these treatments 
produced both improvement in mental health and 
reduction in substance use. In contrast, MI alone 
resulted in only short-term reduction in substance use, 
and CBT alone did not appear to have a significant effect 
on measured treatment outcomes.
I Conclusions
Generic versus cannabis-specific treatment 
programmes for adults
Given the relative dearth of evidence-based cannabis-
specific interventions in the drug research literature and 
the considerable heterogeneity of cannabis use disorder 
patients’ characteristics and treatment needs, the 
diversity of treatment settings, patient populations and 
countries where the studies were conducted is very 
welcome and needed. It seems quite likely that there is 
no ‘one-size-fits-all’ intervention for all these cases.
Most of the effective general and cannabis-specific 
interventions reported in the literature are based on the 
same therapeutic strategies. As no study has 
systematically compared the treatment outcomes (e.g. 
willingness to participate and retention in treatment, 
abstinence, reduction in cannabis use) of cannabis-
specific interventions with those of general substance 
use treatments for cannabis users, the question of the 
superiority of one approach to the other remains 
unanswered. Nevertheless, there are signs that ‘keeping 
treatment specific to cannabis’ can be important in 
facilitating dependent cannabis users to enter treatment.
Dual diagnosis
Individuals with cannabis use and co-morbid psychotic 
or affective disorders (Baker et al., 2010; Hjorthøj et al., 
2009) may not benefit sufficiently from MI or CBT alone; 
they may need a longer or more intensive 
psychotherapeutic treatment, combining MI and CBT 
as it can be administered in less time (e.g. one or two 
sessions) than is required for other treatment 
programmes, yet produces comparable effects.
Smedslund et al. (2011) conducted a meta-analysis of 
the effectiveness of MI for substance use that included 
only randomised controlled trials (59 studies; 13 342 
participants). The results revealed that the effects on 
substance use were strongest when MI was compared 
with no-treatment control groups. Furthermore, the 
effect was stronger at post-intervention and tended to 
attenuate at short- and medium-term follow-up. No 
significant effect was found for long-term follow-up. In 
contrast with the findings from Lundahl et al. (2010), no 
significant difference of effects was found between MI 
and treatment as usual.
The research on the effectiveness of CM shows that it may 
enhance substance use treatment for adults, in a similar 
way to that which has been demonstrated in programmes 
targeting adolescent substance use. Stitzer et al. (2010) 
conducted an incentive-based abstinence programme in a 
large sample of stimulant users (803 participants). In a 
multisite randomised trial, participants were randomly 
assigned to treatment as usual, with or without a prize 
draw incentive programme. Individuals in the incentivised 
condition had a higher retention rate in the treatment 
programme and lower substance use than those in the 
non-incentivised treatment condition. Similar results were 
found in a study of homeless, non-treatment-seeking men 
who have sex with men (Reback et al., 2010). In that study, 
participants in the CM condition achieved greater 
reductions in stimulant, alcohol and methamphetamine 
use than those in the control group. Reductions in 
substance use were maintained at the 9- and 12-month 
follow-up evaluations. While cannabis use was common 
among study participants, cannabis use did not differ 
significantly between the CM group and the control group.
Dual diagnosis
Treatment of patients with dual diagnosis — substance 
use and co-occurring psychiatric problems — has been 
considered in a specific line of investigation. Two reviews 
were identified, which included 48 studies (Table 5). 
Hjorthøj et al. (2009) reviewed the literature on 
treatment of cannabis dependence in individuals with 
schizophrenia spectrum disorders. They found that MI 
alone or CBT alone had no effect on cannabis-related 
treatment outcomes; however, these treatments showed 
efficacy in reducing the use of other substances.
From a review of the literature focusing on cannabis 
treatment for individuals with co-morbid psychotic and 
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a very efficient adjunct to the treatment of adult 
substance use disorders, where it helps in fostering 
retention or improving substance-related treatment 
outcomes (Dutra et al., 2008). Combinations of MET, CBT 
and CM are also considered the most effective cannabis-
specific treatment approach (Benyamina et al., 2008; 
Danovitch and Gorelick, 2012). Both narrative reviews 
confirm earlier findings from the systematic Cochrane 
review on psychosocial interventions for adults with 
primary cannabis use disorders (Denis et al., 2006).
Adults with cannabis use disorders seem to benefit from 
various intervention types. The strongest and most 
enduring treatment effects are found in secondary 
outcomes such as reductions in the frequency of 
cannabis use, the number of dependence symptoms, the 
severity of cannabis dependence or the number and 
severity of cannabis-related problems (e.g. Danovitch and 
Gorelick, 2012). It has to be noted that moderation and 
harm reduction are not accepted as treatment goals by 
many healthcare providers and other stakeholders (e.g. 
Hoch et al., 2012). Therefore, response rates, particularly 
regarding abstinence from cannabis, leave much room for 
improvement. Questions about the optimal duration, 
intensity and type of treatment, setting and moderating 
factors (e.g. gender, co-morbidity, culture, family 
cohesion) need to be further examined in future research.
I  Research on telephone and online interventions
Most recently, new formats for these approaches have 
been tested. Minimal interventions reported in the 
literature include postal (Norberg et al., 2012), 
computerised (Budney et al., 2011; Carroll et al., 2009; 
Godley, M., et al., 2010; Tossmann et al., 2011) and 
telephone-based interventions (Gates et al., 2012). 
These general or cannabis-specific interventions have 
the potential to increase access to treatment and lead to 
benefits such as reduced substance use, motivation to 
change, retention and increased knowledge about the 
substance. This can be achieved especially in 
uncomplicated cases of substance use and related 
problems (Rooke et al., 2013). However, Hoch et al. 
(2014) argue that tele-interventions cannot completely 
replace a live clinician, as some patients may be 
unwilling to use web-based interventions or need 
personal assistance as a result of complex impairment 
and more severe problems.
Here we review research into interventions using 
telecommunications — Internet, telephone, messaging 
with standard pharmacotherapy (Baker et al., 2010). 
However, there is a notable lack of studies addressing 
cannabis use disorder patients with schizophrenia 
spectrum disorders or anxiety disorders and individuals 
with further dual diagnoses (e.g. alcohol use disorders, 
polydrug use, ADHD, personality disorders). Knowledge 
about how to treat these highly prevalent medical 
conditions remains very limited.
Intervention types
As described in the narrative review section of this 
report, various empirically supported treatments are 
available for adults with cannabis use disorders. 
Randomised studies have been performed on different 
combinations of MET, CBT and CM. One study combined 
psychosocial problem solving, as developed by D’Zurilla 
and Goldfried (1971), with MET and CBT (Hoch et al., 
2012). These efficacy studies were mostly conducted in 
clinical settings with a limited number of study sites. No 
published studies on family interventions for adults with 
cannabis use disorders were found. Twelve-step 
programmes were absent from the literature on 
psychosocial interventions for cannabis dependence, 
unlike that on other substance use disorders. Their 
utilisation, long-term efficacy and potential role as an 
integrated component of psychosocial interventions for 
cannabis dependence have not been examined until 
now. Notably, no individual empirically supported 
treatment emerged as being significantly more effective 
than any other empirically supported treatment. 
Because the underpinnings of these therapeutic models 
are complementary, researchers have focused less on 
treatment superiority and more on identifying effective 
combinations (Danovitch and Gorelick, 2012).
Treatment effects
Aggregated empirical evidence on general substance use 
treatments indicates that motivational enhancement has 
small effects on substance use in adult patient 
populations (Lundahl et al., 2010). Effects were largest at 
post-treatment and when MI was compared with no 
treatment (Smedslund et al., 2011). Compared with a 
specific treatment or treatment as usual, no significant 
effects were found (Lundahl et al., 2010; Smedslund et al., 
2011). All of the systematic reviews and meta-analyses 
consistently found that a combination of MET and CBT is 
most effective in reducing the frequency and quantity of 
substance use, as well as the severity of substance 
use-related problems and mental health problems. 
Whereas CM has not always been seen as a practical 
strategy for many clinicians, evidence suggests that CM is 
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Tossmann et al. (2011) conducted a randomised 
controlled study evaluating the effectiveness of a 
3-month online drug-related information and prevention 
programme. Cannabis users seeking web-based 
treatment were recruited to participate in the study and 
were assigned to either a waiting list control condition or 
the treatment condition. Of the 1 292 subjects included 
in the trial, a total of 206 took part in both the pre-test 
and post-test assessments. Participants in the treatment 
condition showed a significantly stronger reduction in 
cannabis use than those in the control group. In the 
per-protocol analyses, moderate to strong effects were 
found for reduction in the frequency of cannabis use and 
the quantity of cannabis consumed. Small to moderate 
effects were observed on secondary outcomes (e.g. 
use-related self-efficacy, anxiety, depression and life 
satisfaction). The same research group (Jonas et al., 
2012) evaluated the effectiveness of a one-session, 
online intervention based on MI. Young alcohol and 
cannabis users (302 participants) were randomised to 
either a group that received chat-based MI or a group 
that received feedback on a previous self-test. Intention-
to-treat analysis yielded no differences between the 
groups. In both groups, there was a significant time-
effect in alcohol use and readiness to change. Another 
approach, using a mobile phone as a medium, was 
tested by Laursen (2010). Based on qualitative 
interviews, she found initial evidence that information on 
cannabis use delivered via short message service (SMS) 
could help young people reduce their consumption of 
cannabis.
Interventions for substance use disorders delivered via 
telephone have also been shown to be effective. Godley, 
M., et al. (2010) examined whether telephone-based 
continuing care was as effective as usual continuing care 
in preventing substance use relapse. Participants were 
randomised into one of the two treatment groups. At the 
3-month follow-up, participants in the telephone-based 
care group reported significantly fewer substance-
related problems than the face-to-face group; however, 
significant differences were not found at the 6-month 
follow-up. Gates et al. (2012) expanded on the Godley, 
M., et al. (2010) study. In a randomised controlled trial, 
they examined the efficacy of a telephone-based 
cannabis use intervention. The 160 participants were 
randomised to a telephone-based intervention that 
contained components of CBT and MI or to a delayed 
treatment control condition. Results revealed that the 
participants in the treatment condition exhibited greater 
reductions in dependence symptoms and substance-
related problems at both follow-up assessments. 
Furthermore, they reported greater confidence in their 
ability to reduce cannabis use at four weeks and a 
greater percentage of abstinent days at 12 weeks.
services — to reach clients and treat cannabis use 
disorders. The characteristics of the studies included in 
the present analysis can be found in Table 7.
Studies conducted to date have produced promising 
outcomes in the treatment of numerous behavioural and 
psychological disorders. Reviewing 12 studies of 
computer-based interventions for drug use disorders, for 
example, Moore et al. (2011) found that, compared with 
treatment as usual, computer-based interventions led to 
less substance use, higher motivation to change, better 
retention and greater knowledge of presented 
information.
In the field of substance use disorders, Carroll et al. 
(2008) examined whether biweekly access to computer-
based training adds incremental value to standard CBT 
treatment in an outpatient community setting. The 77 
participants were randomly assigned to standard 
treatment or standard treatment plus computer-based 
training in CBT (CBT4CBT). The results revealed that 
participants in the CBT4CBT group had significantly 
fewer positive urine specimens and exhibited longer 
continuous periods of abstinence during treatment. 
Carroll et al. (2009) followed up this research with a 
study examining whether CBT4CBT was more effective 
than treatment as usual over a 6-month period. Results 
revealed that, compared with those in the treatment as 
usual condition, participants in the CBT4CBT condition 
slightly reduced their substance use over the course of 
the study period. The effect remained significant even 
after controlling for treatment retention, substance use 
outcomes and exposure to other treatment during the 
follow-up period.
Sinadinovic et al. (2012) examined the effectiveness of an 
Internet-based screening and brief intervention (eScreen.
se) on reducing substance use. The 202 participants were 
randomised to either the treatment condition or an 
assessment-only control group. Although both groups 
showed a significant decrease in self-reported substance 
use, the Internet-based treatment group exhibited a 
significantly larger decrease in substance use frequency.
Budney et al. (2011) published results of a feasibility 
study comparing a computer-delivered version of MET/
CBT/CM with a therapist-delivered version. For the 
non-randomised, 12-week comparison study, 38 adults 
were assigned to either the computer-delivered MET/
CBT/CM or the therapist-delivered MET/CBT/CM. No 
significant differences were found between the conditions 
in terms of attendance, retention and cannabis use 
outcomes. Although these results are promising, they 
need to be replicated in studies using randomised 
controlled designs before firm conclusions can be drawn.
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The type of substance used and the type of treatment 
provided may not be the only determinants of treatment 
success. Rather, there are several moderating factors 
that have a profound impact on the effectiveness of 
treatment. For instance, Hendriks et al. (2012) found in a 
secondary analysis that co-morbid psychiatric problems 
moderated the effectiveness of different substance use 
treatment modalities. They found that MDFT was more 
effective for adolescents with a previous diagnosis of 
conduct disorder, oppositional defiant disorder or 
internalising problems. Participants without these 
co-morbid psychiatric conditions benefited much more 
from CBT. In addition, Hendriks et al. found evidence that 
older adolescents (17–18 years old) benefited more from 
CBT, whereas younger adolescents benefited more from 
MDFT. Additionally, Stein, L., et al. (2011) found some 
evidence for moderating effects of depression on the 
effectiveness of treatment for cannabis use among 
incarcerated adolescents. Their study demonstrated that 
MI significantly reduced cannabis use among 
incarcerated adolescents, but only in a group with low 
depression symptoms. Relaxation training was a more 
effective approach for adolescents in their sample with 
high depression symptoms.
Some research suggests that cultural factors may 
moderate the effectiveness of substance use treatment. 
A study comparing the effectiveness of a culturally 
adapted version of CBT and standard CBT for substance 
use in Latino adolescents found that treatment 
outcomes were moderated by ethnic identity and 
familism (Burrow-Sanchez and Wrona, 2012). 
Specifically, their results revealed that Latino 
adolescents with high levels of ethnic identity and 
familism benefited significantly more from the culturally 
adapted treatment than Latino adolescents who were 
low on these cultural variables. In addition, Robbins et al. 
(2008) compared the effectiveness of regular BSFT and 
BSFT enhanced with ecological interventions. Latino 
adolescents benefited more from the ecologically 
enhanced BSFT, but African American adolescents did 
not, suggesting that ethnicity may moderate treatment 
effectiveness in some cases.
Family-level factors may also moderate the effectiveness 
of substance use treatment. In an unpublished study, 
Mermelstein (2011) examined the influence of family 
cohesion on substance use severity in adolescents 
admitted to a residential substance use treatment 
centre. Results suggested that family cohesion level was 
significantly and inversely related to substance use 
severity. In agreement with these findings, Henderson et 
al. (2009) found that improved parental monitoring of 
the adolescent partially mediated the effect of MDFT on 
reduced substance use. Perhaps some of the 
Tait et al. (2013) conducted a systematic review of 10 
randomised controlled studies, which included about 
4 125 participants aged 11 years or older. The authors 
concluded that Internet treatment can reduce cannabis 
use in the short term.
I Conclusions
Telephone and online interventions are still under 
investigation. Nevertheless, they can offer a good 
opportunity for those who are not prepared to seek 
treatment in healthcare centres, and especially for 
young people, who are very comfortable with the use of 
the Internet and telecommunications. Moreover, the 
relatively low costs can be appealing, especially for 
countries that are facing the prospect of providing 
treatment for large numbers of intensive cannabis 
users.
I  Factors and mechanisms influencing effectiveness
In addition to studies investigating the effectiveness of 
treatment, some researchers have tried to identify the 
determinants of treatment success (see Table 8).
Bergmark (2008) cites results that indicated that 
increases in treatment dosage did not produce 
significantly better treatment outcomes for adolescents. 
This result is consistent with previous research 
indicating that even brief interventions can influence 
cannabis use. For example, McCambridge and Strang 
(2005) found that a 1-hour face-to-face MI session 
significantly reduced weekly frequency of cannabis use 
compared with a no-treatment group. These findings 
have major real-world implications for the 
implementation of effective cannabis-treatment 
protocols, including the potential for reduced cost and 
increased availability of treatment.
Tanner-Smith et al. (2013) found that longer duration of 
general substance use treatment was associated with 
smaller improvements. This is in agreement with earlier 
work that suggests that longer duration of treatment 
does not necessarily produce better treatment 
outcomes (Dennis et al., 2004).
A brief intervention targeting risky behaviours associated 
with cannabis use was shown to reduce risky cannabis-
related behaviour (e.g. driving after cannabis use) in a 
sample of college students (Fischer et al., 2013).
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methods and the formats used. Type of intervention and 
treatment intensity (i.e. number and frequency of 
therapy sessions) varied largely, too. In most studies, the 
patients were randomly assigned to an active 
intervention and to a comparison. The latter was either 
an alternative active intervention or combination of 
interventions, treatment as usual or a delayed treatment 
control. Measures of substance use were provided 
through self-report or self-report combined with 
biochemical measures of substance use. Outcome 
variables measured at baseline and assessed at follow-
up included, for example, abstinence, quantity and 
frequency of cannabis use and other substance use, 
number and severity of use-related problems, DSM-IV 
dependence symptoms and other problem behaviours. 
Studies generally reported following study participants 
for periods of between 1 and 12 months. Most studies 
provided information on loss of study participants over 
time, which is a common occurrence in clinical trials. The 
number of study dropouts was counted and a retention 
rate was calculated. Methodologically strong studies 
included measures of quality assurance, for example 
using a manual to guide the intervention, providing 
training and supervision of study counsellors, and 
assessing treatment fidelity using audio or video 
recordings of the therapy sessions.
I  Recent findings in perspective
The results of this review are in line with findings 
previously published by the EMCDDA (Bergmark, 2008). 
All of the studies included in Bergmark’s review were 
consistent in that they found that cannabis dependence 
treatment, regardless of modality, was more likely to 
result in abstinence than no treatment (Budney et al., 
2000, 2006; Carroll et al., 2006; Copeland et al., 2001; 
Marijuana Treatment Project Research Group, 2004; 
Stephens et al., 2000). It remained unclear, however, 
whether the relative effectiveness of the treatment 
depended more on the type of treatment offered or the 
duration of the treatment. The Marijuana Treatment 
Project Research Group (2004) found some evidence 
suggesting that brief interventions were somewhat less 
effective than longer interventions; however, more 
research is needed in this area before firm conclusions 
can be reached.
Bergmark (2008) also reviewed several studies 
comparing the effectiveness of different treatment 
modalities. The treatments that were reviewed included 
MET, CBT, CM and combinations of these approaches. 
Based on his review, Bergmark concluded that a 
combination of MI interventions, behavioural and 
effectiveness of family-based treatments for substance 
use disorders is because these treatments also address 
family-level factors that can moderate the effectiveness 
of treatment.
Therapeutic alliance serves as a major factor influencing 
the effectiveness of treatment in a variety of domains 
(Martin et al., 2000) and, therefore, is likely to play a key 
role in determining the effectiveness of substance use 
treatment. Garner et al. (2008) examined whether 
therapeutic alliance influenced the effectiveness of 
substance use treatment. They found that adolescents 
reporting higher levels of therapeutic alliance also 
reported higher levels of social support and greater 
problem recognition and had more reasons for quitting. 
Moreover, they found that therapists tended to report a 
higher level of therapeutic alliance with older 
adolescents, suggesting that adolescent age may serve 
as an additional factor moderating treatment 
effectiveness.
Kadden and Litt (2011) reviewed literature examining 
whether increases in self-efficacy mediate the 
association between substance use treatment and 
successful treatment outcomes. The results of their 
review indicate that self-efficacy is an important 
mediator of the effectiveness of substance use 
treatment. In addition, their results revealed that 
self-efficacy may serve as a moderator of treatment 
effectiveness, such that individuals who are high in 
self-efficacy exhibit better treatment outcomes.
Stein, M., et al. (2011) found that initial desire to quit 
may be an important predictor or moderator of 
treatment outcome, regardless of the specific 
substance use treatment that is utilised, such that 
individuals with a high initial desire to refrain from 
substance use are more likely to have a successful 
treatment outcome.
Finally, the effectiveness of treatment may be moderated 
by characteristics of the population being treated, such 
as gender (Magill and Ray, 2009), involvement in the 
criminal justice system (Carroll et al., 2012) and co-
morbid psychopathology (Baker et al., 2010). Therefore, 
it is important to be aware of factors that may influence 
treatment, in order to find the best match between 
patient and treatment approach.
I  Study characteristics
The studies identified and included in this review were 
heterogeneous in terms of their research designs and 
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cognitive coping skills, and incentives was the most 
effective approach to treatment (Budney et al., 2000; 
Budney et al., 2006).
Bergmark found that a combination of motivational 
interventions, behavioural and cognitive coping skills, 
and incentives was most effective in the treatment of 
cannabis use disorders for adults. Benyamina et al. 
(2008) and Elkashef et al. (2008) supported this 
position. Still, it is worth highlighting the conclusion of 
Danovitch and Gorelick (2012) from their review of 
randomised trials: less than 20 % of those treated for 
cannabis-related problems achieved long-term 
abstinence.
To date, no medication has been found to be broadly 
effective in the treatment of cannabis use disorders, 
although a number of pharmacological approaches are 
being pursued (Danovitch and Gorelick, 2012). 
Psychosocial interventions, mainly focusing on 
psychotherapeutic approaches, are therefore the only 
type of treatment available for this target group.
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The options available for treating individuals with 
cannabis use problems vary widely across the European 
Union. For example, the Netherlands reports one of the 
most comprehensive cannabis-specific treatment 
systems, offering two inpatient and two outpatient 
programmes specialising in the treatment of cannabis-
related problems. These programmes are provided free 
of charge and available to the majority of those in need 
of treatment. In the United Kingdom, cannabis-specific 
treatment programmes are not provided, but 
considerable resources are devoted to treating 
individuals with cannabis use disorders through general 
substance use programmes, which may be tailored to 
individual needs on a case-by-case basis. This chapter 
brings together information from these countries and 28 
others to present, in the first part, an overview on the 
approaches to treating cannabis use disorders across 
Europe, providing the most recent information on the 
programmes available in each country. In the second 
part, selected cannabis-specific programmes offered in 
European countries are described.
I  Treatment availability
I The European picture
Information on the type of treatment offered to those 
with cannabis-related problems was gathered in 2011 
and 2013. In 2011, out of the 30 countries affiliated to 
the EMCDDA, 17 reported the provision of substance-
specific treatment for cannabis-related problems. This 
information was updated in 2013 by a survey of national 
focal points (CSTNFPS) conducted by the authors of this 
report. When the information provided through this 
survey is combined with the 2011 data, it emerges that 
cannabis-specific treatment programmes are available in 
15 countries (Figure 2). As more than one-third of the 
Member States did not provide updated information in 
the 2013 survey, it is not possible to make a definitive 
statement on whether the number of European countries 
offering cannabis-specific programmes had increased or 
decreased since 2011 (Table 9).
FIGURE 2
Existence of specialised treatment programmes  
for cannabis users in European countries
Cannabis-specic
treatment is available
General substance
treatment only
Source: SQ27 dataset (section on specific cannabis treatment), 2011; 
Cannabis-Specific Treatment National Focal Point Survey (CSTNFPS), 
2013.
In both 2011 and 2013, countries were asked to provide 
expert assessments of the coverage of treatment relative 
to needs — that is, the proportion of those in need 
estimated to have access to treatment (see Table 9 for 
rating scale). In the 2011 survey, of the 18 countries 
reporting provision of cannabis-specific treatment, 8 
reported that treatment coverage was rare or limited and 
10 reported extensive or full treatment coverage. Five 
countries stated that they were planning to implement 
cannabis-specific treatment approaches by 2014.
The main focus of this overview is cannabis-specific 
treatment. Where no specific intervention was reported, 
information is provided on how generalised substance 
use services cater for the needs of those with cannabis 
problems.
CHAPTER 3
Treatment of cannabis use disorders 
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TABLE 9
Availability of cannabis-specific treatment (CST) in European countries
Country CST available CST coverage (1) Implementation of 
CST planned (2)
Type of treatment offered
Belgium Yes Full n.a. CBT, MDFT, MI
Bulgaria (3) No n.a. Yes n.a.
Czech Republic (3) Yes Rare n.a. –
Denmark Yes Full n.a. CBT
Germany Yes Extensive n.a. CANDIS, CAN Stop, Quit the Shit, Realize It!, MDFT
Estonia No n.a. Yes n.a.
Ireland (3) No n.a. No n.a.
Greece Yes Full n.a. –
Spain No n.a. – n.a.
France No n.a. No n.a.
Croatia (3) Yes Full n.a. –
Italy (3) Yes Extensive n.a. –
Cyprus No n.a. Yes n.a.
Latvia No n.a. No n.a.
Lithuania (3) Yes Extensive n.a. –
Luxembourg (3) Yes Extensive n.a. CANDIS
Hungary No n.a. Yes n.a.
Malta No n.a. – n.a.
Netherlands Yes Extensive n.a. MDFT, CBT
Austria (4) Yes – n.a. CANDIS 
Poland Yes Rare n.a. CANDIS (5)
Portugal Yes Limited n.a. –
Romania (3) Yes Limited n.a. –
Slovenia No n.a. – n.a.
Slovakia Yes Full n.a. CBT, MI
Finland No n.a. – n.a.
Sweden (4) Yes Extensive n.a.
United Kingdom No n.a. – n.a.
Turkey (3) No n.a. – n.a.
Norway (3) Yes Limited n.a. Out of the Fog
(1)  Expert rating. Rating scale: full: nearly all people in need of help would obtain it; extensive, a majority but not nearly all of them would obtain it; limited, 
more than a few but not a majority of them would obtain it; rare, just a few of them would obtain it.
(2)  Implementation of specific cannabis treatment is planned within the next three years.
(3) No information for 2013 or later.
(4) Information from national focal point, 2014.
(5) Personal communication, Hoch, 2014.
Abbreviations: CBT, cognitive behavioural therapy; MDFT, multidimensional family therapy; MI, motivational interviewing; n.a., not applicable; –, no information 
available.
Source: SQ27 dataset (section on cannabis-specific treatment), 2011; Cannabis-Specific Treatment National Focal Point Survey (CSTNFPS), 2013.
For further information see the EMCDDA Annual report 2012, pp. 42–43, and the 2012 Statistical bulletin (available at emcdda.europa.eu/stats12).
I Country descriptions
The most recent information available on treatment  
for cannabis use disorders in each of the 28 EU  
Member States, Turkey and Norway is presented  
in this section.
Belgium
Belgium provides cannabis-specific treatment through 
the Cannabis Clinic. Adolescents with cannabis use 
problems are offered MDFT, and adults with cannabis 
use problems are offered CBT, MI and group therapy. 
National coverage of the affected population is rated as 
comprehensive, as nearly all individuals in need of 
treatment are estimated to have access to a cannabis-
specific treatment programme. Treatment is 
administered in an outpatient setting.
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programmes for adolescents with cannabis use 
problems. These programmes include CANDIS, Quit 
the Shit, Realize It, MDFT and CAN Stop. The available 
programmes use a range of modalities, including 
individual therapy, group therapy, systems therapy and 
Internet-based counselling. All cannabis-specific 
interventions in Germany are offered on an outpatient 
basis. The majority of individuals in need of treatment 
for cannabis use disorders in Germany are estimated to 
have access to treatment through a cannabis-specific 
programme.
More information about cannabis-specific programmes 
offered in Germany can be found on the following 
websites:
n  CANDIS: candis-projekt.de
n  Realize It: realize-it.org
n  Quit the Shit: quit-the-shit.net
n  CAN Stop: canstop.med.uni-rostock.de
Estonia
Estonia does not offer cannabis-specific treatment 
programmes. Nevertheless, general substance use 
treatment is available to all those who wish to receive 
treatment for problems related to cannabis use. 
Treatment for cannabis use disorders is typically 
provided in psychiatric hospitals through individual 
substance use treatment plans.
Ireland
Ireland does not offer cannabis-specific treatment 
programmes. Individuals with cannabis use problems 
receive psychological outpatient interventions in the 
context of the general substance use treatment system. 
No additional information is available on the types of 
interventions offered.
Greece
Greece offers a family systems cannabis-specific 
treatment programme through the ATRAPOS early 
intervention programme. The programme draws 
interventions from MDFT and multisystemic therapy and 
is targeted specifically at adolescents and young adults. 
In addition, 11 other treatment programmes offered in 
the country mainly treat problem cannabis users; 
however, these programmes are not cannabis-specific. 
All available programmes are offered on an outpatient 
basis.
For more information about the Cannabis Clinic, visit the 
website chu-brugmann.be/fr/med/psy/cannabis.asp
Bulgaria
According to the most recent available data, cannabis-
specific treatment programmes are not offered in Bulgaria. 
Individuals with cannabis use problems typically receive 
psychosocial treatment that is tailored to their individual 
symptoms and needs. The majority of patients with 
cannabis use problems are treated via non-governmental 
organisations, public and private clinics, in outpatient 
settings and through Internet-based consultations.
Czech Republic
The Czech Republic reports the existence of a cannabis-
specific treatment programme. However, no additional 
information is available about the type of treatment 
provided or the settings in which treatment is 
administered. In the Czech Republic, coverage of the 
affected population is rated as very limited, as only a 
small percentage of individuals in need of treatment for 
cannabis use problems are estimated to have access to 
cannabis-specific treatment.
Denmark
Cannabis-specific treatment programmes are available 
throughout Denmark. While most large municipalities 
offer one, the nature of the programme offered differs 
from municipality to municipality. Cannabis treatment 
programmes offered in Denmark are seldom manual-
based, predetermined cannabis programmes; rather, the 
treatment programmes are based on a variety of 
cognitive behavioural and psychoeducational techniques 
adjusted to the particular group of clients receiving 
treatment. Admission to cannabis-specific treatment in 
Denmark is open only to those who cite cannabis as their 
principal drug of use. The majority of the available 
programmes are based on individual counselling and 
psychotherapy. Special programmes are also offered for 
adolescents with cannabis use disorders. Coverage of 
the affected population in Denmark is rated as extensive, 
as the majority of those who are in need of treatment are 
estimated to have access to it.
Germany
Germany offers a variety of cannabis-specific 
treatment programmes, including specialised 
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through the programme. Coverage of treatment for 
cannabis-related problems is rated as comprehensive, 
as nearly all those in need are estimated to have access 
to treatment. In addition, substance use treatments are 
available that are targeted specifically at adolescents, 
including those with cannabis-related problems.
More information about treatment for cannabis-related 
problems in France can be found on the website 
drogues.gouv.fr/etre-aide/lieux-daccueil/
consultations-jeunes-consommateurs/
Croatia
Croatia reported offering a cannabis-specific treatment 
programme in 2011. Updated information on the status 
of this programme is not available. The most recent 
estimate indicates that nearly all those in need have 
access to treatment for cannabis use. Treatment is 
provided via counselling centres specialising in the 
treatment of cannabis users.
Italy
Italy offers cannabis-specific treatment programmes, but 
no information is available on the type of treatment 
offered or the setting in which treatment is typically 
administered. The most recent estimate indicates that 
the majority of those in need of treatment for cannabis 
use problems in Italy have access to cannabis-specific 
treatment programmes.
Cyprus
Cyprus does not offer a cannabis-specific treatment 
programme. In Cyprus, individuals with cannabis use 
problems are treated in outpatient facilities that primarily 
provide psychosocial treatments. Treatment for cannabis 
users is mainly provided by public agencies specialising 
in adolescent drug treatment, as well as by private 
clinics and non-governmental organisations.
Latvia
In Latvia, cannabis-specific treatment programmes are 
not available. According to the most recent data, 
treatment for individuals with cannabis use problems is 
provided in outpatient settings and involves 
psychosocial interventions. Additional information on 
the specific nature of the psychosocial interventions is 
not available.
More information about the ATRAPOS programme can 
be found on the website okana.gr
Spain
Cannabis-specific treatment programmes are not 
offered in Spain. Most of the substance use treatment 
programmes follow a ‘patient type’ approach as opposed 
to a ‘substance’ approach. Nevertheless, individuals with 
cannabis use problems who require professional support 
or treatment can receive free, government-subsidised 
treatment, in both inpatient and outpatient settings. 
Spain offers three treatment programmes, described 
below.
The Abuse/Addiction Treatment Programme for Adults is 
administered in drug addiction centres in Madrid. The 
intervention uses biopsychosocial interventions and is 
provided by a multidisciplinary team. Treatment is 
administered in both individual and group formats. A 
substantial proportion of those treated through this 
programme use cannabis as their primary drug.
The Abuse/Addiction Treatment Programme for Young 
People is targeted at individuals younger than 25 years 
old. This treatment programme is also administered in 
drug addiction centres in Madrid. Adolescents and 
young adults with substance use problems are treated 
by a specialised team according to a specific treatment 
protocol. In 2012, 84 % of the 14- to 18-year-olds and 
66 % of the 19- to 24-year-olds who received treatment 
through this programme reported cannabis as their 
primary drug.
The Prevention Programme is aimed at users who have 
been penalised by the criminal justice system for drug 
use or possession. The programme is designed to 
prevent the development of dependency in casual users. 
In 2012, 81 % of those referred to the programme had 
been penalised for a cannabis-related offence.
France
France does not offer cannabis-specific treatment 
programmes. However, the Consultations Jeunes 
Consommateurs programme was initially introduced as 
a prevention programme for cannabis users. The scope 
of the treatment programme was expanded in 2008 to 
include all illicit substances used by adolescents and 
young adults. So, while these centres are no longer seen 
as cannabis-specific programmes in France, this 
substance continues to be the most common primary 
illicit substance among individuals receiving treatment 
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programmes are estimated to be accessible to the 
majority of individuals in need of treatment.
More information about cannabis-specific programmes 
offered in the Netherlands can be found on the following 
websites:
CBT and MDFT: brijder.nl/Verslaving/zorgprogramma/
hulp-voor-jongeren,intensieve-gezinsbehandeling
Mistral: brijder.nl/Service/contact/locaties-zuid-holland
Bauhuus: vnn.nl/advies-hulp/jongeren/opname-in-een-
kliniek/bauhuus/
Austria
In November 2013, CANDIS became the first cannabis-
specific treatment programme to operate in Austria. 
Primary cannabis users are often treated in the general 
substance use treatment services. This is particularly the 
case in outpatient settings and has been increasingly 
observed in inpatient settings. For example, about 90 % 
of the participants in the Konsumreduktionsgruppen, a 
general substance use support group offered by Checkit! 
in Vienna, are cannabis users. In fact, when this service 
was initially implemented, the focus was on cannabis. 
Since then, however, the Konsumreduktionsgruppen has 
extended its services to adolescents and young adults 
who use other substances.
Poland
Poland offers CANDIS as a cannabis-specific treatment. 
This programme is provided on an outpatient basis at 
healthcare centres and clinics throughout the country. 
Although 60 drug experts have been trained in this 
programme and 30 services throughout the country 
provide it, the coverage of the affected population is rated 
as limited, as only a small percentage of those in need of 
treatment for cannabis problems are estimated to have 
access to treatment. There are no treatment options 
available that are tailored specifically to adolescents with 
cannabis use disorders. From January 2014, the 
programme has accepted adolescents as well as adults, 
and the number of trained experts has increased to 110 
(Hoch, personal communication, 10 November 2014).
Portugal
Portugal offers cannabis-specific treatment programmes 
within a public network of prevention, treatment and 
Lithuania
Lithuania offers cannabis-specific treatment 
programmes that involve counselling, detoxification, 
psychosocial interventions and rehabilitation. The 
majority of those in need of treatment for cannabis use 
problems are estimated to have access to treatment. No 
additional information is available on the specific types 
of treatment programmes that are offered or the settings 
in which treatment is administered.
Luxembourg
Luxembourg offers cannabis-specific treatment 
programmes, which also include CANDIS (Hoch, 
personal communication, 10 November 2014). Coverage 
of the affected population is rated as extensive, as the 
majority of those in need of treatment for cannabis use 
problems are estimated to have access to treatment. No 
additional information is available on the specific types 
of treatment programmes that are offered or the settings 
in which treatment is administered.
Hungary
In Hungary, cannabis-specific treatment programmes 
are not available. Those with problems related to 
cannabis use, as well as individuals with problems 
related to other substances, are treated by public service 
providers, non-governmental organisations and 
commercial services providing general outpatient and 
inpatient substance use treatment. Treatment includes 
medically assisted interventions and psychosocial 
interventions.
Malta
Malta does not offer cannabis-specific treatment 
programmes. No additional information is available on 
treatment for cannabis use problems in this country.
Netherlands
The Netherlands has one of the most comprehensive 
cannabis-specific treatment systems in the European 
Union. The country offers a variety of cannabis-specific 
programmes in both inpatient and outpatient settings. 
Outpatient options include CBT and MDFT (for 
adolescents and young adults). Inpatient cannabis-
specific treatment is offered through the Mistral and 
Bauhuus clinical programmes. These treatment 
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Finland
Finland does not offer cannabis-specific treatment 
programmes. Specialised treatment for those with 
substance use problems include outpatient care 
(A-Clinics, youth centres), short-term inpatient care 
(detoxification units), longer-term rehabilitative care 
(rehabilitation units), support services (day clinics, 
housing services and subsidised housing) and peer 
support activities. In addition to the units providing 
specialised services for those with substance use 
problems, increasing numbers are treated within primary 
social and healthcare services, including social welfare 
offices, child welfare services, mental health clinics, 
health centre clinics, hospitals and psychiatric hospitals. 
The Finnish system emphasises that substance use 
treatment alone is often insufficient and that the 
individual in treatment should receive assistance in 
solving problems related to income, living situation and 
employment.
Sweden
No information is available regarding the availability  
of treatment for cannabis use problems  
in Sweden.
United Kingdom
The United Kingdom adheres to an inclusive view of 
substance use treatment and has implemented services 
that are tailored to individual needs. Thus, there are only 
a few cannabis-specific services or groups, and these 
services are often part of a larger substance use 
treatment service. Most interventions for treating 
cannabis-related problems are provided as part of the 
wider substance use treatment system. The mainstay of 
treatment is evidence-based psychosocial 
interventions. The United Kingdom also has young 
people’s substance misuse services, which are 
commissioned and delivered separately from adult 
substance use treatment. The majority of adolescents 
and young adults accessing specialist drug and alcohol 
interventions have problems with alcohol (37 %) or 
cannabis (53 %). Treatment for young adults and 
adolescents often involves psychosocial, harm 
reduction and family interventions, rather than 
treatment for addiction, which is required by most of the 
adults but only some of the young people referred for 
treatment for cannabis use.
More information about the treatment of cannabis use 
disorders in the United Kingdom can be found in the UK 
rehabilitation centres (called CRIs, centres for integrated 
responses). CRIs are accessible throughout the country, 
providing a nationwide network of coverage for drug 
addiction interventions. Each CRI develops an 
intervention for at-risk cannabis users who do not yet 
meet the criteria for abuse or dependence. Interventions 
are based on a targeted prevention framework, which 
includes psychoeducation, counselling and social skills 
training. Referral for more intensive treatment will occur if 
it is judged to be necessary. The PIAC programme 
administered at a CRI in Oporto is an example of a 
programme that treats cannabis abuse and dependence. 
The interventions typically involve psychotherapy and only 
seldom require a combination of psychopharmacotherapy 
and psychotherapy. If psychiatric co-morbidity is present, 
it is addressed in specialised CRI units. The CRI at UD-C 
Taipas in Lisbon is an example of this type of intervention.
Romania
The most recent available data indicate that Romania 
offers cannabis-specific treatment programmes; 
however, coverage of the affected population is rated as 
very limited, as only a small percentage of those in need 
of treatment are estimated to receive treatment through 
the available programmes. No additional information is 
available on the types of treatments offered and the 
settings in which treatment is administered in Romania.
Slovenia
Slovenia does not offer cannabis-specific treatment 
programmes. Treatment for individuals with cannabis 
use problems is provided by non-governmental 
organisations and public health institutions. No 
additional information is available about treatment 
options for cannabis-related problems in this country.
Slovakia
Slovakia provides cannabis-specific treatment 
programmes in both outpatient and inpatient settings. 
The cannabis-specific programmes in Slovakia are based 
on CBT and MET interventions. Coverage of the affected 
population is rated as comprehensive, as nearly all 
individuals in need of treatment are estimated to have 
access to treatment. Special programmes do not exist 
for adolescents with cannabis use problems.
More information about the treatment of cannabis use 
disorders in Slovakia can be found on the website  
cpldz.sk/
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I  Selected cannabis-specific treatment programmes in Europe
A number of programmes have been developed in 
Europe specifically to treat people with cannabis-related 
disorders. For a better understanding of the concepts 
behind these programmes and to provide, where 
possible well-evaluated, examples of such programmes, 
this chapter examines some of them in more detail. 
While it is not intended to give a comprehensive 
description of all available cannabis-specific 
interventions in Europe, the major cannabis-specific 
treatment programmes currently existing in Europe are 
included here.
An overview of selected programmes is presented at the 
end of the section, listing the European countries where 
these interventions have been implemented (Table 10).
I  Realize It
Realize It is a cannabis-specific treatment programme 
for adolescents and young adults aged between 15 and 
clinical guidelines (National Treatment Agency for 
Substance Misuse, 2007).
Turkey
Turkey does not offer cannabis-specific treatment 
programmes. Available data indicate that those with 
cannabis use problems receive detoxification treatment 
followed by psychosocial treatments. No additional 
information is available on the treatment of those with 
cannabis-related problems in Turkey.
Norway
Norway offers a cannabis-specific treatment programme, 
Ut av taka (Out of the Fog). The programme has two target 
populations: (1) adolescents and young adults with 
cannabis-related problems and (2) employees in urban 
districts whose day-to-day work involves contact with 
affected young people. The programme is a group-oriented 
outpatient treatment. Coverage is rated as limited, 
however, as only a few of those in need of treatment are 
estimated to have access to the programme.
Individual session I: Introduction to treatment programme, create a self-monitoring diary, define individual goals 
regarding cannabis use (within the programme period), define specific goal to be accomplished by the next session.
Individual session II: Two modules:
n  Evaluate progress towards goal 1 n  Problem solving
n  Define goal 2 n  Reduce cannabis consumption
Individual session III: Self-control strategies:
n  Evaluate progress towards goal 2 n  Identify risky situations
n  Define goal 3 n  Develop coping strategies
Individual session IV: n  Overcome stressful situations
n  Evaluate progress towards goal 3 n  Plan a cannabis-free spare time activity
n  Define goal 4 
Individual session V: Evaluate progress towards goal 4 and overall treatment goal.
Group sessions: Group sessions are focused on increasing awareness of risky situations and the development of 
coping strategies. The counsellor serves as a moderator of group discussions. Group sessions last two hours, take 
place on a weekly basis and contain between three and six participants. Participants are strongly encouraged to 
attend at least one group session during the course of treatment. 
Source: Realize It overview obtained from the Realize It programme manager on 27 June 2013.
Realize It
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30 years. The programme includes five individual 
sessions and at least one group session. Individuals who 
exhibit signs of problematic alcohol use or limited 
problem-solving skills have the option of participating in 
a 3-session alcohol reduction module, a 3-session 
problem-solving skills module or both. Thus, the typical 
dose of treatment ranges from 6 to 12 sessions. The 
individual sessions are based on the principles of brief 
solution-focused therapy (Berg and Miller, 2000). 
Individuals in treatment learn how to define individual 
behavioural goals with regard to their problem cannabis 
use. In addition, a major objective of the treatment 
programme is to help clients develop self-regulation and 
self-control skills. For instance, clients learn how to 
identify successful strategies for limiting cannabis use 
by examining their entries in a drug diary. The group 
session provides individuals in treatment with an 
opportunity to share their successful strategies with 
others. Communication between the counsellor and 
clients in both the individual and group sessions relies 
heavily on the principles of MI. At present, this 
programme is available only in Germany, where it is 
offered in outpatient drug-counselling centres and is 
administered by social workers.
More information about Realize It can be found on the 
website: realize-it.org
I  CANDIS
CANDIS (Hoch et al., 2012) is an outpatient intervention for 
adolescents (over 16 years old) and adults that was created 
specifically to treat cannabis use disorders. The 
programme is empirically supported in the treatment of 
problem cannabis use. This intervention is offered only in 
an individual therapy format and the standard dose of 
treatment is 10 sessions, spanning a period of 8 to 12 
weeks. CANDIS consists of three programme modules: (1) 
MET, (2) CBT and (3) psychosocial problem-solving training 
(PPT). The aim of the programme may be either total 
abstinence from cannabis or reduction in cannabis use. 
Treatments, such as CANDIS, which combine aspects of 
CBT and MI have been shown in empirical research to be 
efficacious treatments for cannabis use disorders.
CANDIS is currently offered in Germany, Austria, 
Luxembourg, Poland and Switzerland. In Germany, CANDIS 
is administered by psychologists, psychiatrists and social 
workers. The programme is primarily provided in outpatient 
settings, but is sometimes offered in inpatient settings in 
Germany. In Poland, CANDIS is conducted by addiction 
therapy specialists in outpatient facilities.
Conceptual elements of CANDIS
Motivational enhancement therapy (MET)
n  Miller and Rollnick (2002)
n  Interventions to stimulate motivation to change
Cognitive behavioural therapy (CBT)
n  Aetiology of cannabis use disorder (biological, 
psychological, social aspects)
n  Understanding cannabis use patterns (functional analysis)
n  Development of an individual change concept and goal 
setting
n  Quit day preparation (skills training, stimulus control 
and enforcement of alternative behaviours)
n  Relapse prevention (strategies to cope with urges, 
craving and high-risk situations)
n  Improve social skills, cannabis refusal skills and social 
support
n  Management of co-morbid mental disorders (anxiety, 
depression, substance use disorders)
Psychosocial problem-solving training (PPT)
n  D’Zurilla and Goldfried (1971)
n  Identify and solve problems
Standard sessions in CANDIS
n  Session 1: Diagnostic feedback and enhancement of 
motivation to change
n  Session 2: Enhancement of motivation to change
n  Session 3: Understanding cannabis use patterns
n  Session 4: Goal setting and target day preparation
n  Session 5: Debriefing of target day and management 
of craving
n  Session 6: Relapse prevention
n  Session 7: Psychosocial problem solving
n  Session 8: Psychosocial problem solving
n  Session 9: Co-morbidity
n  Session 10: Social skills training and treatment 
termination
Source: Hoch et al. (2011)
For more information about CANDIS in Germany and 
Poland see candis-projekt.de
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I  CAN Stop
CAN Stop is an intervention for adolescent 
and early adult cannabis users (aged 
14–21 years) offered throughout Germany. 
The CAN Stop programme consists of 
eight 90-minute group treatment sessions. Group size 
typically ranges from 6 to 12 clients. The treatment 
programme primarily uses CBT and MI interventions and 
Session 1: You CAN Stop!
Participants are introduced to the Can Stop group training model. The trainer informs participants about the 
schedule and the group rules. Following a ‘get to know each other’ exercise, participants begin to build up an 
atmosphere of trust. Then, the diary in which participants will document their cannabis consumption is explained 
with the help of examples. In the second part of the session, participants are asked to reflect on the disadvantages 
and advantages of consuming cannabis.
Session 2: Knowledge is power!
Participants receive psychoeducation on the consequences of cannabis consumption for the brain and general 
health. Subsequently, participants complete a 15-question quiz addressing topics relating to cannabis 
consumption including origin, active ingredients, addiction, impact on health, detectability, psychosis and legal 
matters. With the help of illustrations and diagrams, processes in the brain are explained. Furthermore, 
participants learn the criteria of addiction and rate their own status on a scale from ‘non-problematic’ to ‘misuse’ 
or ‘addiction’.
Session 3: Find your strengths!
Diary entries are evaluated and discussed. First, achievements in reducing cannabis consumption are reinforced. 
The main focus in this session is identifying individual strengths and resources that can help change cannabis 
consumption behaviour. The aim is to promote positive self-perception and strengthen participants’ self-confidence.
Session 4: Express your emotions!
The role of emotions in cannabis consumption is discussed, as emotions often trigger consumption. Participants 
are instructed to think about how typical consumption situations are associated with their emotional state. In the 
second part of the session, participants work together in the group to develop alternative coping strategies for 
dealing with these emotions.
Session 5: Doesn’t everyone get stoned?
The fifth and sixth sessions focus on the topic ‘Cannabis and peers’. In Session 5, the perceived norms of 
participants’ own consumption are contrasted with peer norms. Subsequently, the participants’ own social 
environment is discussed. Participants then reflect specifically on the interaction between the peer group and 
consumption behaviour. Acquaintances and friends who are abstinent are praised and cannabis-independent 
interests are reinforced. With the help of the group, concrete steps to reconnect with abstinent contacts or friends 
are developed.
Session 6: Just say No!
The main focus of the sixth session is tempting social situations and the refusal of cannabis use in these 
situations. On the basis of their diary entries, participants are instructed to identify typical individual (social) 
CAN Stop: treatment overview (1)
techniques. CAN Stop is conducted by laypeople, that is, 
individuals from a broad range of professional 
backgrounds who have experience working with the 
target group and who have attended a one-day training 
seminar. CAN Stop was specifically developed in such a 
way that it could be easily implemented in various 
contexts. It is currently offered in inpatient and outpatient 
medical settings, juvenile detention facilities and 
substance use treatment settings.
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Much of the effort involved in Out of the Fog is directed 
towards training personnel and working together with city 
wards in Oslo to enable them, in the longer term, to run 
these courses on their own and offer them to young 
people in their ward. Some city wards have run groups in 
cooperation with Out of the Fog. The wards are also given 
guidance, and there is cooperation on follow-up. The 
project is also working on making the ‘quit smoking hash’ 
course and method better known and on developing the 
methodology. In total, 98 people were followed up through 
the project in the first half of 2012. This is more than in the 
whole of 2011, when the total number was 64.
Similar courses aimed at weaning people off cannabis are 
also held in several other Norwegian towns and cities. 
Such courses may reach young people who would not 
otherwise seek help for their drug problems. Increased 
focus on and knowledge about cannabis use problems in 
social and healthcare services will enable more young 
people to seek help for their problems at an earlier stage 
(see the 2012 Reitox national report for Norway).
I  Out of the Fog
The Out of the Fog (Ut av tåka) cannabis-specific 
intervention is designed to target two groups: (1) 
adolescents and young adults (aged 15–25 years) who 
are motivated to stop using cannabis and (2) first-line 
employees (e.g. teachers, mentors, social workers) in 
urban districts who come into contact with these 
individuals on a daily basis. The programme emphasises 
the integral role played by multisystemic support in 
reducing cannabis use.
The Out of the Fog ‘quit smoking hash’ course in Oslo 
involves intersectoral cooperation and aims to develop 
local competence and methods, based on experiences 
from Sweden and Denmark. The initiative has helped 
professionals to offer young people in their city ward an 
opportunity to quit smoking cannabis, both through 
groups and individually. Young people are reached 
earlier than they were before.
situations that are tempting. The aim is to increase awareness of situations where there is an increased risk of 
consumption. On this basis, strategies are developed to help participants cope with such situations and to enable 
them to avoid cannabis use.
Session 7: Relapse prevention
The aim of the seventh session is to identify individual signs or predictors of relapse and to find strategies to 
prevent relapse. Using their diaries, participants explore their individual consumption and risk situations and 
group them into different risk categories in accordance with Marlatt’s risk classification system. Finally, they rank 
their risk situations. With the help of a role-play exercise and the ‘angel-devil-dialogue’ metaphor, associations 
between cognitions and cannabis consumption are discussed. Playful cognitive and behaviour strategies are 
developed to avoid future risky situations.
Session 8: Emergency and goodbye
In the eighth session, the aim is to consolidate what has been learnt so far. Furthermore, an emergency plan is 
developed. The difference between a ‘slip’ and a full relapse is explained. The participants search for possible 
reinforcers for abstinence and connect their programme goals (e.g. abstinence or reduction) with a concrete 
symbol. Finally, participants create an individual ‘emergency kit’ in the form of a matchbox that contains helpful 
cognitions. The programme closes with the presentation of an individual certificate to each participant.
Source: CAN Stop treatment overview obtained from CAN Stop programme manager on 27 June 2013.
More information about CAN Stop can be found on the website canstop.med.uni-rostock.de
(1) Translated from German.
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I  Quit the Shit
Quit the Shit (Tossmann et al., 2011) is an Internet-based 
counselling programme that takes place over a 50-day 
period. The programme targets adolescents and young 
adults, and the interventions used in the programme are 
based on solution-focused therapy. Thus, interventions 
are geared towards helping the client to establish 
effective self-control and self-regulation skills. Quit the 
Shit is administered by trained counsellors over email 
and through online chat. The programme is free and, 
since it is offered online, can be used anonymously. The 
programme consists of four consecutive phases: (1) 
registration, (2) admission chat, (3) online diary and 
feedback, and (4) termination chat. The registration 
phase involves gathering personal information from the 
client that is relevant to substance use counselling and 
programme evaluation. After the client has registered for 
the programme, the admission phase begins. This phase 
involves an initial 50-minute online chat with a 
counsellor. The objective of this chat is to clarify the 
client’s substance use situation, determine cannabis use 
goals and identify coping strategies. After admission, the 
online diary is activated. Clients record all relevant 
aspects of their cannabis use in an online diary for the 
next 50 days. During this period, clients receive written 
feedback once a week from their counsellor. The 
feedback relates to cannabis use levels, the 
psychosocial situation of the participant and the 
counselling process. On completion of the 50-day online 
diary phase, the counsellor conducts a termination chat 
with the client. The objective of this chat is to review 
progress towards the client’s cannabis use goals, 
identify which individual strategies were most effective 
in reducing cannabis use and determine whether further 
professional help is required.
Screening: evaluate stage of change (transtheoretical model), obtain sociodemographic data, evaluate for 
cannabis use or dependence (DSM-IV), determine patterns of cannabis consumption
One-on-one chat:
n  Introduction to treatment programme, creation of 
cannabis use diary, definition of individual goals 
(within the programme period).
50-day diary:
n  Self-monitoring.
n  Document consumption patterns.
n  Daily summary .
Six modules:
n  Identify disadvantages and advantages of consuming 
cannabis.
n  Identify risky situations.
n  Come up with alternative (drug-free) activities.
n  Write farewell letter to substance.
n  Develop and implement problem-solving skills.
n  Identify personal strengths and resources.
n  Read weekly written feedback:
n  Motivation enhancement.
n  Develop coping strategies.
Final chat evaluating progress towards treatment goals and providing referral if necessary
Source: Quit the Shit treatment programme overview obtained from the Quit the Shit treatment programme 
manager on 27 June 2013.
More information about Quit the Shit can be found on the website quit-the-shit.net
Treatment of cannabis-related disorders in Europe
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treated in outpatient settings. Second, those entering 
inpatient treatment are often referred from outpatient 
services, raising the possibility of double-counting and 
thereby overestimating the overall numbers entering 
treatment for cannabis problems.
As treatment monitoring in many countries covers only 
parts of the drug treatment system, a correction factor 
for under-coverage (as reported by the national focal 
points) was used to calculate the total number of treated 
cases.
The resulting numbers are presented in Figure 3. The 
ratio of treated cases per daily or near-daily user is 
understood as a rough indicator of the coverage of 
treatment needs for those with cannabis-related 
problems.
Considerable variation exists between countries in the 
ratio between the number of treated cases with 
cannabis as the primary drug and the number of daily or 
near-daily cannabis users. Seven out of the 15 countries 
The last chapter showed how European countries vary in 
the way they handle treatment needs for cannabis-
related problems. Some focus on special programmes 
and approaches whereas others use a more generic 
system of treatment provision, which can be adapted to 
needs at an individual level. The extent to which 
treatment needs are met by any of these treatment 
offers is an important question. In this chapter, estimates 
of treatment provision — taking into account both 
specific and generic approaches — per country are 
presented and discussed in relation to indicators of 
treatment needs.
This approach has to be seen as a first attempt to 
compare needs and provision of treatment for cannabis-
related problems at a European level. In the absence of a 
European instrument to assess the treatment needs of 
this clientele, a proxy indicator is used. Studies have 
shown a high correlation between regular, especially 
daily, use of cannabis and cannabis-related disorders. 
This permits ‘daily or near-daily use’ prevalence to be 
used as a proxy for problematic cannabis use. It is 
assumed that those using the drug daily or almost daily 
would be the target group for cannabis treatment. While 
acknowledging that not all individuals using the drug on 
a daily or near-daily basis would be in need of or would 
benefit from cannabis treatment, the size of this group 
can serve as a crude estimate of possible treatment 
needs.
For each country, a national estimate was calculated 
from (1) the prevalence of cannabis use in the last 
month, as measured in the most recent national surveys, 
and (2) the percentage of daily or near-daily users 
among this group, as reported by national focal points to 
the EMCDDA in a separate study (EMCDDA, 2012b).
Treatment provision was calculated on the basis of 
reports of clients who had been in specialised drug 
treatment in Europe who cited cannabis as their primary 
drug. This information is collected through the treatment 
demand indicator (TDI) for each calendar year. Only 
outpatient treatment numbers were used in the 
calculations for two reasons. First, the majority of 
reported admissions for primary cannabis problems to 
specialised drug treatment facilities in Europe are 
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FIGURE 3
Treated cannabis cases per 100 daily or near-daily 
users
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NB: Treatment data for Denmark, Portugal, Sweden and the United 
Kingdom refer to 2011; data for other countries refer to 2012.
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only a very limited proportion of the population in need 
of treatment. In these countries, and in others with only 
limited treatment availability, additional resources could 
be devoted to programmes aimed at increasing the 
accessibility of quality treatments for those with 
cannabis-related problems.
I  Specific treatment for specific substances?
Looking at treatment offered for cannabis-related 
problems throughout Europe, two approaches are 
evident: (1) cannabis-specific treatment, which is 
targeted at a specific age group (adolescents or young 
adults) and the risks and harms associated with the use 
of the drug, and (2) general substance use treatment, 
which is tailored to the individual needs of the cannabis 
user seeking treatment. In terms of treatment 
organisation and settings, general approaches may 
appear to have certain disadvantages. Treating users of 
different drugs together may lead to mixing of older and 
younger users, more marginalised and problematic users 
and well-integrated users, which is unwanted both by 
public health services and by drug users. By offering only 
for which such detailed data are available report 
between 5 and 10 treatment cases per 100 daily or 
near-daily users. This is equivalent to 1 person receiving 
treatment for each 10 to 20 daily users in a given year. 
Latvia has a still higher value, which reflects the very low 
prevalence of daily cannabis use assessed in the 
country. Some other countries have extremely low ratios 
of around or below 1 per 100.
By adding the level of prevalence to this analysis, it is 
possible to provide national policymakers with an 
indication of how cannabis treatment in their country 
stands both in relation to potential needs and in 
relation to other European countries. As Figure 4 
shows, a high prevalence of daily or near-daily use in 
the population does not always coincide with a high 
level of treatment provision. Two examples of this are 
Spain and Portugal. In these countries, which present a 
rather high prevalence of daily or near-daily cannabis 
use, the ratio of treatment cases to daily or near-daily 
users is very low compared with the European  
average.
Although the majority of the countries report that drug 
treatment is provided to most or all of those asking for it, 
there are still several European countries in which 
available cannabis use treatment programmes cover 
FIGURE 4
Ratio between annual number of cases treated for cannabis use problems per 100 daily or near-daily users and 
prevalence of daily or near-daily cannabis use
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NB: Dashed lines represent average values. Latvia, with a daily use of 0.7 % and 34.2 in treatment per 100 daily users, is off-scale and is not plotted on the 
graph.
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profiles and user groups. The discussion on the 
treatment of drug problems related to new psychoactive 
substances has just started. What lessons can be learnt 
from the past 10 years’ discussion on treatment for 
cannabis use for this target group of ‘recreational users’? 
First, it is important to gather more information on the 
users. More knowledge about their consumption 
patterns, other drugs used and drug-related physical, 
mental and social harms is required to understand the 
possible treatment needs of this specific group of users. 
As with the treatment of those dependent on alcohol, 
nicotine or cannabis, and based on the evidence 
available for patients with substance use disorders, it is 
very likely that combinations of MET, CBT, CM and 
family-based interventions will be effective for this target 
group. General treatment approaches may already exist 
in many treatment services, where staff are trained and 
sufficiently experienced in these approaches.
standard treatment facilities and approaches, services 
may not attract all of the cannabis users who could 
benefit from this type of treatment.
However, comparing the evidence for specific and 
generic interventions, there seems to be no firm basis for 
a conclusion in favour of cannabis-specific treatment: 
both approaches have shown similar levels of effect. This 
is not unexpected, as both types of intervention are built 
on the same psychotherapeutic and educational 
approaches, which have shown their efficiency 
frequently under different conditions: MI, MET and CBT 
for adults, with some additions based on family systems 
theory and therapy for younger people.
While cannabis is by far most the prevalent illicit drug in 
Europe, it is not the only one. There are many other 
substances in use, often changing, with unclear risk 
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The observation of Bergmark (2008) that for cannabis 
use disorders all treatments appear to work still seems 
apt. Our review of the literature published since 2008 
found no conclusive evidence for the superiority of any 
specific treatment to others. Treatment context and the 
individual’s choice in entering treatment are more 
important determinants of outcome than treatment 
modality. The evidence does not show that specialised 
cannabis use treatment offers cannabis users better 
outcomes than general substance use treatment — both 
approaches can work. These findings are reassuring 
given that the options available for treating cannabis-
related problems vary widely across the European Union.
Despite the cooperation of experts in almost all EU 
countries, the picture of cannabis treatment that 
emerges is incomplete. For many of the treatment 
options provided in Europe, especially the general 
substance use approaches, at best only limited 
information is available. In contrast, detailed information 
is available for most of the cannabis-specific 
programmes covered by this study: all of those are 
based on therapeutic strategies with the highest 
evidence for effectiveness — although only four of these 
programmes have been tested for efficacy.
Questions can be raised about how the available 
evidence may inform the treatment of cannabis use 
problems in European countries. Recent research on 
moderators for treatment effectiveness show that 
‘culture’ may be a relevant factor in determining the 
failure or success of an intervention (Burrow-Sanchez 
and Wrona, 2012; Robbins et al., 2008). The evidence 
base, however, is largely made up of published treatment 
studies carried out in the United States or Australia. To 
what extent are published evidence-based CBT 
programmes transferable to diverse European treatment 
settings? Are cultural adaptations of these approaches 
needed? These are research questions that ought to be 
addressed.
Comparing indicators of treatment needs and treatment 
provision, the overall situation in Europe looks positive. 
In most countries, there seems to be an adequate level 
of treatment provision in relation to needs. However, 
some of the countries with quite high levels of use, and 
possibly high levels of need, have reported relatively low 
levels of treatment provision, which may indicate the 
existence of unmet treatment needs.
Although the bulk of cannabis problems are treated in 
outpatient settings, primary cannabis users nevertheless 
account for almost one in every five of those entering 
inpatient drug treatment. Whereas about half of the 
countries offer cannabis-specific outpatient 
interventions, cannabis-specific residential treatment 
options are offered only in the Netherlands and Slovakia. 
Demand for inpatient treatment for cannabis problems is 
likely to increase in the future, if the overall demand for 
cannabis treatment continues to rise.
Internet-based interventions present a promising area 
for further development, as they can reach a much 
broader group of cannabis users, which may benefit 
from preventative and treatment interventions.
Closely related to the issue of rising demand for 
treatment are the legal issues associated with cannabis 
use and treatment. A substantial proportion of those 
presenting with cannabis use problems in Europe are 
referred by the criminal justice system. Changes in 
criminal justice referral practices and the emphasis on 
rehabilitation and treatment over punishment and 
correction will continue to have an impact on who is 
referred for treatment, who receives treatment and, 
ultimately, the availability of treatment in Europe. 
Depending on policy, rates of referrals for treatment 
could increase or decrease regardless of actual changes 
in the prevalence of cannabis-related problems. Issues 
relating to the legal status of cannabis have the potential 
to affect criminal justice referral policy and practice, and 
perhaps even the nature of treatment for cannabis 
problems. For example, decriminalisation of cannabis 
could lead to treatment programmes setting moderation 
of cannabis use, rather than complete abstinence, as a 
treatment goal.
Other directions for the future growth of treatment 
provision in Europe include the implementation of 
adolescent-specific drug use treatment in more 
countries and a growth of multisystemic therapies to 
treat this population. From the data analysed in this 
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heterogeneous group of clients (e.g. co-morbidity, gender, 
referral from the criminal justice system). More effective 
approaches to early interventions and secondary 
prevention are needed for children, teenagers and young 
adults. Moreover, further work is need on improving 
treatment for specific groups of users, including those 
with dual diagnoses, prisoners, female and pregnant 
cannabis abusers and certain groups of elderly cannabis 
abusers. The function of prolonged cannabis-associated 
neurocognitive deficits in the treatment process (and their 
reversibility) needs to be examined, as does the 
effectiveness of cognitive remediation therapy in this 
group of patients. Research into new and effective 
pharmacological approaches to treatment of cannabis 
dependence is still under way and much needed. Finally, 
the questions of treatment organisation and differential 
indication (‘which patient benefits most from an 
intervention, delivered by which type of health 
professional in which setting?’), and the need for 
education, training and case-related supervision for 
treatment providers, need to be addressed.
study, it appears that programmes designed specifically 
for adolescents exist in only half of the countries that 
offer cannabis-specific treatment; the data do not reveal 
how many of the other countries offer treatment 
programmes targeted at adolescents. As adolescents 
account for a large proportion of those with problematic 
cannabis use in the European Union, meeting the needs 
of this population will depend on more countries offering 
adolescent-specific treatments, such as family and 
multisystemic therapy.
The low rates of treatment seeking, retention and 
continuous abstinence (which is still the primary 
treatment goal of treatment providers and health 
insurance companies in many EU countries) associated 
with cannabis treatment may suggest that there is 
considerable room for improvement in the interventions.
As well as the development of new therapeutic strategies, 
a diversification of existing approaches is needed, 
tailoring treatment to the characteristics and needs of this 
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I Glossary
Cannabis: a plant-based substance containing tetrahydrocannabinol (THC), a 
psychoactive substance. In Europe, it is typically marketed in two forms: herbal cannabis 
or ‘marijuana’ and cannabis resin or ‘hashish’. Cannabis is a controlled substance 
throughout the European Union.
Cannabis-specific treatment: a treatment whose target population is limited to individuals 
with cannabis use disorders.
Cannabis use disorders: this term refers to either cannabis abuse or cannabis 
dependence. Both of these disorders are characterised by problematic cannabis use (i.e. 
cannabis use that causes distress, dysfunction or both in the user’s life). Cannabis 
dependence is indicative of a more problematic pattern of use than cannabis abuse. Full 
descriptions of both of these disorders, including symptoms and associated features, can 
be found in the Diagnostic and statistical manual of mental disorders, 4th edition, text 
revision (American Psychiatric Association, 2000).
General substance use treatment: a treatment whose target population is individuals with 
substance use disorders. Thus, treatment is not targeted at users of one specific 
substance.
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About the EMCDDA
The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level. 
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
About this series
EMCDDA Insights are topic-based reports that bring 
together current research and study findings on a 
particular issue in the drugs field. This publication 
reviews the interventions used in the treatment of 
cannabis disorders and maps out the geography  
of cannabis treatment in Europe. 
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